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ABSTRACT
Prostate cancer was the most commonly diagnosed cancer in males in Australia in
2012, with over 18,560 cases. It is estimated that 1 in 9 men in Australia will develop
prostate cancer at one time in their lives, with the risk of being diagnosed by age of
85 close to 1 in 5. In 2011 – 2012, over 2000 prostate cancer patients were treated
by radiation therapy. Brachytherapy accounted for 62% of radiotherapy procedures in
prostate cancer-related hospitalisations over this period.
High Dose Rate (HDR) brachytherapy is the temporary insertion of a radioactive
source directly in or close to a tumour. Small, hollow catheters are inserted into the
treatment region and a remote afterloader is used to drive the highly active radiation
source through each catheter to deliver dose. The remote afterloader fully controls the
placement of the source, by driving it to planned points inside of each catheter, for an
amount of time determined to deliver the planned dose to the tumour.
As there can be complications resulting from an incorrect treatment of HDR
brachytherapy, it is essential that methods and instrumentation for quality assurance
(QA) are available to medical physicists. Direct and accurate verification the treat-
ment plan delivery and the functionality of the remote afterloader are of paramount
importance in ensuring appropriate treatment. Currently, there are no comprehensive
QA solutions available for HDR brachytherapy.
This aim of this thesis is to develop a novel HDR QA system, the "Magic Plate",
using an 11×11 array of silicon epitaxial diodes, fast readout electronics and a software
tool kit, capable of triangulating the HDR source position in three-dimensions. A HDR
brachytherapy specialised casing, the "Magic Phantom", was designed and tested for
pretreatment delivery confirmation of any HDR brachytherapy plan. A feasibility
study was performed to assess the "Magic Plate" in real-time verification during patient
treatment.
KEYWORDS: High dose rate brachytherapy, quality assurance, diode array
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Chapter 1
Introduction
Prostate cancer is the second largest cause of cancer-related death developed by men
in Australia after lung cancer. It is estimated that 1 in 8 men in Australia will develop
prostate cancer by the age of 75, with the risk of being diagnosed by the age of 85 closer
to 1 in 5 [1, 2]. Prostate cancer can be curable when detected early, and appropriate
treatment can be recommended in consideration of the patient’s age and case severity.
The treatment options for prostate cancer in Australia are typically surgical removal
of the whole prostate or radiation therapy [3].
High Dose Rate (HDR) Brachytherapy is a form of internal radiation therapy that
can be used to treat many types of cancers, and is widely used for the treatment of
prostate cancer. It can be used to effectively target the tumour with minimal dose
to adjacent organs, such as the bladder and rectum, because the dose decreases very
rapidly with increased distance from the source. In HDR brachytherapy, thin close-
ended catheters are temporarily inserted into the prostate under ultrasound image
guidance. A single high-intensity source, typically 192Ir, at the end of a flexible steel
cable is connected to a mechanical delivery device known as the remote afterloader,
which is controlled outside the treatment room. The remote afterloader transports
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the source through each catheter, one after another, to preplanned positions inside the
tumour for a the time duration needed to achieve the total prescribed dose. By having
millimetre precision on the inserted source position, HDR brachytherapy provides the
best opportunity to shape and control the final dose delivered to the tumour.
Dose escalation in HDR brachytherapy essentially increases tumour control [4] but
requires strict quality assurance (QA) guidelines due to the extremely high risk of
overdosing normal tissue. While HDR brachytherapy is generally a safe treatment,
there have been many recorded incidents of incorrect treatments [5–7]. The majority
of these were due to human errors, such as the inaccurate entry of source strength
and prescription dose into the afterloader control, improper catheter selection, the
incorrect step size selected, and the wrong transfer tubes and catheters connected [8].
While the likelihood of the remote afterloader itself malfunctioning and incorrectly
administering the treatment is considered low, deviations from the treatment in dwell
times and dwell positions can result in variations in absorbed dose. While it is unknown
what final effect these variations may have on the patient, it has been shown that
multiple interstitial catheter applicators, such as in prostate treatments, would have
the highest susceptibility to these deviations [9]. The incidence of these errors could
be reduced by the introduction of additional pretreatment redundancy checks between
the treatment planning and delivery process [10].
One of the main goals of a quality assurance program for HDR brachytherapy is to
ensure that patient treatments are consistently administered correctly by the remote
afterloader. An accurate treatment delivery means that the source is driven to the
planned position, inside the correct applicator, and for the correct amount of time,
ensuring the calculated absorbed dose matches the prescription set by the radiation
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oncologist [11, 12].
The success of the treatment is dependent on the remote afterloader positional and
timing accuracy, and the verification of this is a fundamental part of an effective
verification program [13,14]. Ideally, performing a confirmation of the planned delivery
on each plan prior to patient treatment would ensure that there are no deviations from
the source dwell positions and times at the time of treatment. For a pretreatment plan
delivery verification system to be feasible in a clinical setting, it should be quick to
perform and require minimal personnel.
The ultimate goal in HDR brachytherapy quality assurance is the ability to assess
the source delivery and delivered dose while the patient is being treated in real time,
referred to as in-vivo verification. Previous studies have had limited successes in this
area due to the large uncertainties and difficulty of achieving an accurate measurement.
As HDR brachytherapy treatments become increasingly complex, the need to develop
delivery verification methods, such as those found in other radiation modalities, is
essential to ensure the optimal treatment of patients [15]. As new technologies and
techniques emerge, there is now an opportunity to develop robust quality assurance
systems for this challenging problem.
1.1 Project aim
The aim of this project is address the current lack of treatment verification in HDR
brachytherapy. This aim is divided into the following objectives:
• Review the current attempts in the literature to develop a quality assurance
system for HDR brachytherapy;
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• Design a prototype system that can be used for both pretreatment and in-vivo
verification;
• Assess the feasibility of the prototype system and develop its use for source
position determination;
• Explore its use in the verification of treatment plan delivery;
• Investigate the system’s potential use in in-vivo verification by testing its ability
to perform source tracking at large distances between the detector and source.
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1.2 Thesis Structure
This thesis consists of 11 chapters that will endeavour to accomplish the aforemen-
tioned project aim and the specific objectives. At the time of thesis completion, three
publications have resulted from this project:
• A. Espinoza, B. Beeksma, M. Petasecca, I. Fuduli, C. Porumb, D. Cutajar, S.
Corde, M. Jackson, M. L. F. Lerch, and A. B. Rosenfeld, "The feasibility study
and characterization of a two-dimensional diode array in "magic phantom" for
high dose rate brachytherapy quality assurance.," Medical Physics, vol. 40, p.
111702, Nov. 2013. [16]
• A. Espinoza, M. Petasecca, I. Fuduli, A. Howie, J. Bucci, S. Corde, M. Jackson,
M. L. F. Lerch, and A. B. Rosenfeld, "The evaluation of a 2D diode array in
"magic phantom" for use in high dose rate brachytherapy pretreatment quality
assurance," Medical Physics, vol. 42, no. 2, pp. 663-673, Feb. 2015. [17]
• A. Espinoza, M. Petasecca, D. Cutajar, I. Fuduli, A. Howie, J. Bucci, S. Corde,
M. Jackson, M. Zaider, M. L. F. Lerch, and A. B. Rosenfeld, "Pretreatment
verification of high dose rate brachytherapy plans using the "magic phantom"
system," Biomedical Physics & Engineering Express, vol. 1, no. 2, 025201, Jul.
2015.
Results published in these papers are found in different chapters of this thesis.
Following this introduction, Chapter 2 begins by providing a background into the use
of HDR brachytherapy, specifically in the field of prostate cancer. It focuses on what
quality assurance practices are needed for this treatment modality and reviews devel-
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opmental approaches found in the literature. As silicon detectors have been chosen
as the basis for this quality assurance system, this chapter will also give a summary
on the theory of semiconductors and their use in radiation detection. A condensed
version of the review of developmental approaches was published in Espinoza et al.
(2013) [16].
Chapter 3 gives a description of the instrumentation used in this project. It begins
by describing the "Magic Plate" detector and the prototype phantom, the "Magic
Phantom", designed for pretreatment verification that has been used. The principle
of operation of the electronic readout, the AFE data acquisition system, is briefly
explained. A software graphical user interface was developed in C++ for the com-
munication to the readout electronics during measurement, and features a complete
analysis tool kit for post-processing. The software has the ability to read DICOM
files used in the planning of high dose rate brachytherapy and can also perform dose
calculations based upon the TG-43U1 protocol. Description of used instrumentation
was published in Espinoza et al. (2015) [17].
The first evaluation of the "Magic Plate" detector for use within HDR brachytherapy
verification is found in Chapter 4. It characterises the system in terms of electronic
noise, range of expected response and angular dependence. Besides identifying the pos-
sible limitations of the system, this characterisation gives the fundamental information
needed to perform a three-dimensional (3D) source localisation calculation. Results
from the angular dependence study were published in Espinoza et al. (2013) [16].
Chapter 5 outlines the fast iterative approach for source localisation in 3D, and the
dwell position and time determination using the "Magic Plate" detector. The following
chapter, Chapter 6, is the experimental evaluation of these methods, primarily focused
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on their use in pretreatment verification. Description of the source tracking algorithm
was published in Espinoza et al. (2013) [16]. The method for dwell position and timing
determination was reported in Espinoza et al. (2015) [17].
This focus on pretreatment verification continues in the following two chapters, Chap-
ters 8 and 9. A method for the comparison between the measured dwell position
and times, and those from the treatment plan was developed and tested in Chapter
8. It features the ability to identify when treatments have been executed differently
to the plan, such as when dwell positions have been introduced or removed during
treatment, and dwell times have varied. The concept and results of the comparison
between measured dwell positions/times to the plan were presented in Espinoza et al.
(2015) [17].
Chapter 9 further develops the concept of the "Magic Plate" as a pretreatment delivery
verification tool, by proposing that the times needed to perform verification can be
shortened by reducing the planned prescription dose. This approach was then applied
to the verification of real patient treatment plans. This work has been reported by
Espinoza et al. [18].
Chapter 7 demonstrates the performance of the high speed tracking of the "Magic
Plate" system, to characterise the motion of the HDR source as it moves between dwell
positions. The dose delivered during this motion, known as transit dose, is generally
overlooked in treatment planning. By combining the high temporal resolution of the
source tracking information and the TG-43U1 protocol for dose calculations, a proof
of concept for transit dose determination was shown.
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The final chapter featuring experimental work, Chapter 10, discusses the feasibility of
the "Magic Plate" for source tracking during patient treatment. The concept of how it
is expected to be achieved is introduced, with some preliminary source tracking results
reported. It considers how inhomogeneities in the body could affect this method, with
measurements performed in phantom with substitute materials.
Chapter 11 concludes this thesis by providing a summary of the outcomes of each
chapter, and provides recommendations for future improvements to the system.
Chapter 2
Literature review
This chapter aims to provide a background on HDR brachytherapy, specifically for
the treatment of prostate cancer. It gives an overview of the prostate’s anatomical
location, the incidence of cancer among males in Australia, and common treatments,
including the use of HDR brachytherapy. It will then examine possible mistakes or
mistreatments that can arise during the delivery of brachytherapy treatment, and
review current and proposed methods of quality assurance.
2.1 The prostate
The prostate is an organ that is part of the male reproductive system and is located
immediately below the bladder, in front of the bowel, surrounding the urethra, as seen
in Figure 2.1. Its main function is to secrete fluids that protect and enrich sperm. A
healthy prostate is about the size of a walnut.
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Figure 2.1: A sagittal view of the prostate relative to the male reproductive anatomy.
Prostate cancer
Prostate cancer is a disease where cells in the prostate gland become abnormal and
grow uncontrollably to form tumours. Cancerous cells in the prostate are generally not
deadly on their own, but are capable of metastasising; spreading to other paths of the
body via the blood or lymph creating new tumours. Benign tumours do not spread
but may interfere with nearby organs and structures, causing secondary problems or
discomfort.
In 2011, 3,294 Australians died due to prostate cancer, making it the fourth largest
cause of death for males. From 2010 to 2020, the projected number of deaths from
prostate cancer is expected to increase to more than 3900 per year [1]. Prostate cancer
is listed as one of the most commonly diagnosed cancers in Australia, with 21,808 new
cases of prostate cancer diagnosed in 2009 alone. It is projected that the incidence
rate will increase to 25,000 new cases per year in 2020. In 2008, the incidence rate in
Australia was found to be higher than in all other countries [19].
The causes of prostate cancer are not clear, but it is known that age is an important
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factor. It is estimated that by age 85, 1 in 5 Australian males will be diagnosed with
prostate cancer [2]. Other considerations for determining the likelihood of increased
risk include family history of prostate cancer, ethnicity, lifestyle and environmental
factors.
Patients with localised prostate cancer i.e. cancer which has not yet metastasised,
have the following options for management, depending on the severity of their case.
For low severity patients, no initial treatment can be recommended with active surveil-
lance typically performed by a general practitioner (GP). Other patients can be recom-
mended the surgical removal of the entire prostate, known as a radical prostatectomy,
or external beam radiotherapy (EBRT) and interstitial radiotherapy (brachytherapy).
Brachytherapy, also known as sealed source or internal radiotherapy, accounted for
62% of radiotherapy procedures in prostate cancer-related hospitalisations between
2011 and 2012 [1].
2.2 High dose rate brachytherapy
Brachytherapy is a radiation therapy treatment where a radiation source is placed
close to or inside the tumour to be irradiated. Radiation is emitted from the source in
all directions, and the intensity decreases following the inverse square law and, coupled
with attenuation in the material, results in steep dose gradients from the source. This
treatment modality allows for a highly conformal dose to be delivered to the tumour
whilst sparing surrounding healthy tissue.
High dose rate (HDR) brachytherapy is the temporal insertion of a single high activity
gamma source, typically Iridium-192 (192Ir), that is used to deliver the prescribed
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dose within minutes. Catheters or applicators are surgically inserted directly into the
prostate gland under transrectal ultrasound guidance. Once all applicators have been
inserted, the patient is re-imaged and the final treatment plan is created to achieve
the prescribed dose coverage.
The advantages of the use of HDR brachytherapy can be summarised as follows [10,
20–22]:
• The introduction of the radioactive source directly into the tumour allows for a
highly localised radiation dose than can be typically achieved with EBRT. This
gives a higher tumour control, which is generally well tolerated.
• The radiation dose attenuates approximately following the inverse square law.
Surrounding healthy tissue receive low dose and side effects can be minimised.
• The overall duration of the treatment is short. Besides ease of treatment for the
patient, this can also prevent proliferation of the tumour tissue.
• The total dose distribution can be highly conformed to the tumour shape, based
upon the planned dwell positions and times.
• The use of remote afterloaders to control the position of the HDR source allows
for much less exposure to medical personnel.
• The patient is not radioactive after receiving the treatment, as opposed to those
receiving permanently implanted radiation seeds.
• Research has shown a radiobiological advantage for prostate cancer when using
HDR brachytherapy compared to using EBRT.
There are, however, some disadvantages:
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• As each treatment gives a large dose, there are increased risks associated with
incorrect delivery or planning.
• The risk of accidental radiation exposure to patients and operators should the
source fail to retract.
• The increased need for accurate dosimetric, anatomic and geometric information
for planning and delivery.
2.3 Treatment planning and delivery
HDR brachytherapy treatment is recommended to patients by the radiation oncologist
based upon the risk category of the case, age of the patient and localisation of the
cancer growth. Prior to the procedure, the patient is placed under an anaesthetic,
such as spinal, epidural or general, and using transrectal ultrasound (TRUS) imaging,
the shape and size of the prostate gland is determined. Catheters are inserted into
the prostate, via the perineum, under the guidance of ultrasound imaging - which can
be used for intra-operative treatment planning. If this is not the case, a post-implant
CT scan of the patient is used to determine the position of the catheters inside of the
prostate and becomes the basis of the treatment plan.
The prostate volume, organs at risk (OAR), planning target volume (PTV) and the
positions of the catheters are defined using a dedicated workstation, known as the
treatment planning system (TPS). For this thesis Nucletron ONCENTRA R© TPS ver-
sion 4.5 (Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden) was used
to perform the treatment planning. The system then determines the placement and
dwell times of the HDR source in each catheter that would effectively shape the dose
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distribution to the prostate volume.
The catheters inside the patient are connected to the HDR treatment delivery device,
known as the remote afterloader. The afterloader is used to control the placement of
the 192Ir source through each catheter. The 192Ir source is connected to a cable wound
around a drum inside the HDR afterloader. While the afterloader is not in operation,
the source is housed inside a shielded lead safe in the afterloader. During treatment,
the drum is rotated by stepping motors to push the source on the steel cables through
a specific channel that connects to the catheter. By varying the source positions and
dwell times, an integral dose distribution can be formed that conforms to the target
volume of the clinical plan [23]. For patients receiving high dose rate brachytherapy as
a monotherapy, the following doses have been recommended: 34 – 38 Gy in 4 fractions,
31-33 Gy in 3 fractions or 26 Gy in 2 fractions [24].
Two of the more common HDR remote afterloaders were used for the experimental
components of this thesis. These were the Nucletron microSelectron R© mHDR-v.2.
afterloader, and the newer Nucletron Flexitron R© HDR afterloader, shown in Figure 2.2,
both produced by Nucletron (Nucletron, an Elekta company, Elekta AB, Stockholm,
Sweden). The Nucletron microSelectron R© mHDR-v.2. afterloader allows up to 30
catheters to be connected for a single treatment plan, with a selectable step size of 2.5,
5 or 10 mm, with a stated positional accuracy of ± 1 mm at each dwell position. The
Nucletron Flexitron R© HDR afterloader supports up to 40 catheters, with a minimum
step size of 1 mm. The stated accuracy of the positioning of this device is ± 0.5
mm at each dwell position. A minimum dwell time of 0.1 s can be selected for both
afterloaders.
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Figure 2.2: The Nucletron microSelectron R© mHDR-v.2. afterloader and the Nucletron
Flexitron R© HDR afterloader, produced by Nucletron (Nucletron, an Elekta company,
Elekta AB, Stockholm, Sweden).
Both HDR afterloaders utilise 192Ir as the radiation source, but have different capsule
designs, resulting in differences to the dose distributions in water. These distributions
are determined experimentally or using Monte Carlo particle transport simulations to
provide the parameters for treatment planning models used in the TG-43U1 protocol.
Each HDR source is modelled following their design specification to create a source
specific set of TG-43U1 parameters.
The HDR afterloader theory of operation
Figure 2.3 shows a schematic of the mechanical components inside of the HDR after-
loader [25]. Inside the afterloader are two separate motor and control systems, one to
drive the HDR source and the other to drive the check cable. The check cable contains
a welded tip made of a solid cylindrical piece of metal, shaped similar to that of the
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192Ir source capsule. The check cable tip does not contain any radioactive material
and is used to test each transfer tube and catheter for blockages and shorter than
expected catheter lengths.
Source shaft encoder
Source stepper motor
Check cable stepper motor
Check cable shaft encoder
Tungstan safe
Emergency stop motor
Channel 1
Channel 18
Cable drum
Cable drum
Indexer stepper
motor
Channel selection
tube
Indexer
disk
HDR source
Check cable
Reference
optopair
Figure 2.3: Sketch of the mechanics of the Nucletron microSelectron R© mHDR-v.2.
afterloader [25].
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The source capsule and check cable tip are located in the afterloader’s tungstan safe
when not in use and the opposite end of the each cable is wound around a cable drum.
Both the source and check cable are driven by independent stepper motors that are
coupled to each cable drum, and are controlled by the system microprocessor. The
source and check cable tip can be positioned inside of the applicator and retracted,
based upon the angular rotation of the cable drum. A shaft encoder of each motor is
used to verify the drum rotation, and conveys the information to the microprocessor
by a series of pulses.
There are two channels inside of the safe for the source and check cable. These join
into a single channel that extends to the indexer stepper motor shaft and into the se-
lected afterloader channel, via the channel selection tube. The indexer stepper motor,
controlled by the microprocessor, is used to rotate the channel selection tube to re-
quired afterloader channel. A separate encoder based upon the rotation of the indexer
disk with the stepper motor is used to provide the microprocessor with the channel
selected information.
The microprocessor positions the source and check cable tip, one at a time, by count-
ing the movement steps of the stepper motor, starting from a reference point. The
reference point is determined by an optopair system, which detects when the source
or check cable has passed between the optopair light and sensor. The system then
checks that the number of steps required to drive the cables back to the reference
point corresponds to the number of steps driven out, with slight variation allowed to
account for friction inside of the transfer tube and applicators.
There is an emergency stop motor that can be used to retract the source cable in
the event of unacceptable differences in steps or a failure to return the source to the
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safe. This motor is powered by a DC power supply with a backup battery, allowing
it to operate independently from the mains power. The emergency motor is able to
withdraw the source with a larger force than the stepper motor by a factor of five,
increasing the chance of retracting the source.
The afterloader system features a primary timer which is used to count down from the
total dwell times for all programmed dwell positions in the treatment. The secondary
timer keeps a running total of all dwell times, plus source transit time to and from the
safe for the movement inside of a single channel. The secondary timer must not exceed
or be significantly less than the sum of the planned dwell times per channel, plus twice
the source transit time within a certain tolerance. A failure of timing occurs when the
maximum difference exceeds 1% or 0.1 s, causing automatic source retraction.
Both timers are managed by the afterloader system and has a minimum time unit
of 0.1 s, but is accurate to 0.01 s [26]. The minimum dwell time than can be set or
resolved is thus 0.1 s, which can potentially lead to rounding errors in timing.
2.4 The 192Ir source
The most commonly used radioactive isotope for HDR brachytherapy is 192Ir. It
is produced by neutron bombardment of the stable 191Ir and results in a minimal
production of unwanted isotopes. Due to its high specific activity and relative ease of
production, sources with very large activities can be manufactured.
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Photon Mean Energy (keV) Intensity (gamma/ 100 decay)
X L 9.440 3.92
X Kα2 65.122 2.62
X Kα1 66.831 4.44
X Kβ3 75.368 0.531
X Kβ2 75.749 1.021
X Kβ1 77.831 0.364
γ 136.39 0.199
γ 176.98 0.0043
γ 280.27 0.008
γ 295.957 28.71
γ 308.455 29.70
γ 316.506 82.86
γ 416.468 0.67
γ 468.068 47.84
γ 485.301 0.0047
γ 588.581 4.522
γ 593.63 0.042
γ 599.41 0.0039
γ 604.411 8.216
γ 612.462 5.34
γ 765.8 0.0013
γ 884.537 0.292
γ 1061.49 0.0531
γ 1089.96 0.0012
γ 1378.5 0.0014
Table 2.1: The 192Ir gamma spectra obtained from the NuDat database [27].
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192Ir has a half-life of 73.827 days, and for HDR brachytherapy treatment, institutions
typically receive a new source with an air kerma strength of 41 mGy.m2.h−1 and replace
their 192Ir source 3 – 4 times a year when it has decayed to 14 – 16 mGy.m2.h−1.
192Ir decays by β− emission to 192Pt (95.13%) and through electron capture to 192Os
(4.87%). On average, 2.21 photons are emitted by both decay processes resulting in
an average energy of the emitted photons of 354 keV.
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Figure 2.4: Components of 192Ir dose as a function of distance. Reproduced from data
obtained by Taylor and Rogers [28] for the Nucletron microSelectron R© mHDR-v.2.
afterloader source.
Simulations performed by Meli et al. [29] show that in a water volume the average
photon energy decreases with increasing distance from the source, to 337, 258 and 221
keV at depths of 1, 5 and 10 cm, respectively. The contribution of energy deposited
for the 192Ir Nucletron microSelectron R© mHDR-v.2. afterloader source obtained by
Taylor and Rogers [28], reproduced in Figure 2.4, shows that with increasing depth
there is a decrease in the dose due to primary photons emitted by the source, but a
larger contribution due to single and multiple scattering. This softening of the spectra
can be problematic for measurement devices and dosimeters that exhibit an energy
2.5. The TG-43 protocol 21
dependence.
2.5 The TG-43 protocol
The Radiation Therapy Committee of the American Association of Physicists in
Medicine (AAPM) formed Task Group 43 and its subsequent update (TG43-U1) to
recommend a dosimetry protocol for dose calculations in water and data sets for the
values of dosimetry parameters for interstitial brachytherapy [30,31]. From this arose
source strength specifications, calibration standards and dose calculation definitions
and equations, which form the basis of many TPS dose calculations from a single
source. The geometry used for point dose calculations is seen in Figure 2.5, where r
is the distance (cm) from the centre of the active source to the point of interest; r0
is the reference distance, specified to 1 cm in this protocol; θ is the polar angle that
specifies the point-of-interest P (r, θ), relative to the source longitudinal axis; and the
θ0 is the reference angle, specified to be 90◦.
P(r,θ)
z
L
t
θ1 θ2
θ3
P(r0,θ0)
r0 = 1 cm
β
Figure 2.5: Point dose calculation using TG-43U1.
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The two-dimensional dose-rate equation is described as
Ḋ(r, θ) = Sk · Λ ·
GL(r0, θ)
GL(r0, θ0)
· gL(r) · F (r, θ) (2.1)
with each function having parameters that have been calculated using Monte Carlo
simulation methods or by dose in water measurements.
Air Kerma Strength, SK
The air kerma strength is defined as
SK = K̇δ(d) · d2 (2.2)
and is the air kerma rate, K̇δ(d) in a vacuum, and due to photons of energy greater
than δ, at distance d, multiplied by the square of distance, d2. The distance, d, is
typically taken at 1 m on the transverse plane, so that it is much larger in comparison
to the source size to eliminate geometry effects. Corrections must be made for the
effects of the attenuation and scatter in air and photon scatter from nearby media
such as walls, floors and ceilings. The unit of air kerma strength is denoted by U,
where 1 U = 1 µGy.m2.h−1.
Dose-rate Constant, Λ
The dose-rate constant in water is defined as
Λ = Ḋ(r0, θ0)
SK
(2.3)
and is the ratio of dose rate at the reference position, P (r0, θ0) and Sk. This quantity
relates the air kerma strength of a source to the dose rate at a reference point in a
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water phantom. It is radionuclide and source model dependent, and has the units of
cGy.h−1.U−1.
Geometry Factor, G(r)
The geometry factor is used to improve the accuracy of the dose rates which can be
estimated by interpolation from data determined at discrete points. This factor pro-
vides an inverse square-law correction based upon the approximate spatial distribution
of radioactivity in the source. For point source approximations, the geometry factor
is
GP (r, θ) =
1
r2
(2.4)
For line source approximations, the geometry factor is calculated for two conditions
GL(r, θ) =

β
L · r · sin θ if θ 6= 0
◦
(r2 − L2/4)−1 if θ = 0◦
(2.5)
where θ is angle of the source with respect to the point of calculation, L is the length
of the source and β is the angle subtended by both ends of the source to the point of
calculation.
Radial Dose Function, g(r)
The radial dose function, g(r), accounts for the dose fall-off on the transverse plane
due to the photon attenuation and scattering through the medium. It is calculated by
g(r) = Ḋ(r, θ0)G(r0), θ0
Ḋ(r0, θ0G(r, θ0)
(2.6)
and can be determined for both the point and line source approximations.
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Anisotropy Function, F(r,θ)
The two dimensional anisotropy function, F(r,θ), is defined as
F (r, θ) = Ḋ(r, θ)GL(r, θ0)
Ḋ(r, θ0)GL(r, θ)
(2.7)
This is used to take into account the differences in dose rate due to the activity distri-
bution in the source, and photon attenuation in the source itself and its encapsulation.
Along the transverse plane of the source, the anisotropy factor is defined as 1.
Summary of the TG-43U1 protocol
The TG-43U1 protocol is currently the worldwide standard for photon-emiting brachyther-
apy dose calculations, and is widely adopted for HDR brachytherapy 192Ir dose plan-
ning. This model is typically based upon Monte Carlo simulations and is strictly valid
only for a homogeneous water phantom, of the size and shape used to obtain the model
parameters [32]. While fast to implement within the clinic, the issues of tissue and
applicator heterogeneities, and the finite patient dimensions are all ignored [33].
This has led to the development of model-based dose-calculation algorithms (MBD-
CAs) where radiation transport could be modelled in non-water mediums, realising
more physically accurate determinations of the dose delivered to the patient. A de-
scription of guidelines for MBDCAs is found in the AAPM Report of the Task Group
186 [32]. Throughout this thesis, the use of the TG-43U1 protocol for dose calculations
has been considered, from the TPS and based upon measurements of source position.
The TG-43 parameters for the Nucletron microSelectron R© mHDR-v.2. source and
Nucletron Flexitron R© HDR Flexisource were obtained from Taylor and Rogers [28].
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2.6 The need for quality assurance in HDR
brachytherapy
HDR brachytherapy involves minimal fractionations, short treatment times and large
doses administered within seconds. It is therefore essential that treatments are deliv-
ered with high accuracy, as errors could result in severe complications [5, 34]. While
HDR brachytherapy is generally regarded as a safe treatment modality, there have
been many events recorded that have led to patient mistreatments. More than 500
HDR accidents, including one death, have been reported along the entire chain of
procedures from source packing to delivery of dose [5].
The majority of these mistreatments were due to human errors, such as the inaccurate
entry of source strength and prescription dose into the treatment planning and after-
loader console, and improper catheter selection. Other common errors were the use of
wrong step sizes in the treatment planning or the afterloader control program, wrong
transfer tubes connected to the remote afterloader, and the incorrect lengths of tubes
and catheter [8]. While the likelihood of the remote afterloader malfunctioning and
incorrectly administering the treatment is considered low, deviations from the plan
in dwell positions and times can result in variations in delivered dose. It has been
shown that the use of multiple interstitial catheter applicators, such as in prostate
treatments, would have the highest susceptibility to these deviations [9].
As HDR brachytherapy planning becomes increasingly complex, it is important to
develop treatment delivery verification methods to ensure optimum treatment of pa-
tients [15]. One of the fundamental goals of an effective quality assurance program
for HDR brachytherapy is to ensure that treatments are consistently administered
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correctly by the remote afterloader, as the success of the treatment is dependent on
positional and timing accuracy [13,14].
As recommended by the AAPM Radiation Therapy Task Group No.59, institutions
should make the minimisation of the likelihood of treatment errors a high priority in
the HDR working environment and procedure flow [10]. A quality assurance program
should exploit redundancy, and review the entire proposed delivery process to iso-
late any actions vulnerable to errors. The incidence of these errors could be reduced
by the introduction of additional pretreatment quality assurance checks between the
treatment planning and delivery process.
An accurate treatment delivery means that the source is driven to the planned position,
in the correct applicator, for the correct amount of time, ensuring the calculated
absorbed dose matches the prescription set by the radiation oncologist [11,12]. An ideal
system for HDR brachytherapy treatment verification should be able to provide the
real-time identification of the dwell positions, measure the dwell and transit times, and
compare these parameters with the prescribed treatment plan both before and during
treatment. The AAPM ratified that to guarantee a "good" quality assurance program,
the medical physicist should be able to accurately measure the source position, timing,
transit velocity and the delivered dose distribution [11]. A sound QA program will
thus ensure the correct operational procedure and will reveal and prevent possible
mistakes, allowing for the safe execution of a treatment in regards to patients and
staff.
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2.7 Current methods of quality assurance
While there are guidelines detailing the quality assurance process for the entire HDR
brachytherapy procedure work flow and safety systems [10,35,36], there is an absence
of a comprehensive treatment delivery verification system within the clinical environ-
ment. Delivery verification of the source position and dwell timer accuracy of the
HDR afterloader is typically performed in the clinical environment using rudimentary
devices.
Source position accuracy
The verification of the positional accuracy requires that the planned sequence of dwell
positions is delivered to the correct position in the correct applicator [11]. According to
the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM)
recommendations [35], the source positional accuracy test must be performed daily.
This can be carried out by exposing the source position onto radiographic film with
markings or with a specialised source position check ruler, seen in Figure 2.6. The
source position can be verified by focussing the treatment suite camera on the source
position check ruler during a QA run. For most QA protocols the typical tolerance
range is 1 mm, where action is to be taken when the inaccuracy is larger than 2
mm. This accuracy has been found to be affected by curved applicators and transfer
tubes [37,38].
Figure 2.6: The source position check ruler.
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Dwell time accuracy
A treatment delivery system achieves temporal accuracy if each planned dwell time
remains at its intended position for the length of time specified by the treatment
plan [11]. The remote afterloader has an electronic timer that is typically verified
using a stopwatch, and performed in combination with the source position catheter
ruler test. For most QA protocols the typical tolerance range is 1%, where action
is to be taken when the inaccuracy is larger than 2%. The influence of the source
transit time is recommended to be taken into account when performing the dwell
time accuracy, as some afterloaders reduce the actual dwell time of the source to
compensate for this. Another potential issue is the "rounding error" that is introduced
when exporting the treatment plan to the afterloader control unit, and even dwell
times less than 0.1 s can be rounded down to 0.
2.8 Pretreatment and in-vivo verification
In the literature there are several studies that investigate different HDR brachytherapy
quality assurance approaches. The goal of the majority of these studies was to develop
a method of localising the source dwell positions and measure timing patterns. The
following review is arranged chronologically, except when discussing a series of related
investigations.
Early pretreatment verification of the source position was performed by Evans et
al. [39]. The method presented was to irradiate film using the HDR source and to
superimpose an x-ray image of dummy cable markers. A HDR treatment catheter
was attached to x-ray film using tape and the afterloader was programmed to dwell
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the source across the catheter with equal dwell times and a 20 mm step size. The
catheter was then detached from the afterloader, and a dummy cable was inserted
into the catheter, still attached to the film. This dummy cable had markers at 10 mm
intervals, which when imaged by a diagnostic x-ray, were used to verify the spacing
and relative position of the HDR source.
The feasibility of treatment monitoring using x-ray fluoroscopy and an anti-scatter grid
was investigated by Sheikh-Bagheri and Munro [40]. EGS4 Monte Carlo was used to
simulate the interactions of the 192Ir and diagnostic x-rays photons inside a phantom,
anti-scatter grid and fluoroscopy detector. They concluded that, in principle, this
method could be used to monitor the delivery of the HDR source, but was considered
difficult to implement in the clinical environment due to constraints on the physical
size of the equipment needed.
A real-time in-treatment source position monitoring system using pinhole imaging was
investigated by Duan et al. [41]. The technique, typically used in nuclear medicine,
coupled a pinhole collimator with a radiographic screen-film and x-ray fluoroscope.
The system used a dual-pinhole placed away from the phantom and reconstructed
the dwell positions in three dimensions using a triangulation algorithm. The authors
reported an average difference of 0.72 ± 0.05 mm between the reconstructed and
planned positions. The fluoroscopy machine allowed for recording of the measurement
of the image onto a standard VCR video-tape for post-treatment verification. While
able to reconstruct the source position in post-processing of film, this method relied
on the user to notice any significant deviations in position via the fluoroscope screen
during actual treatment.
Nakano et al. [42] proposed a proof of principle using a minimum of three detectors
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for HDR three-dimensional source localisation during treatment. Commercial diamond
detectors were investigated for their use in HDR by measuring their directional and
temperature dependence and characterising their response over varying distances from
the HDR source. The intended method was expected to localise the source position
with an accuracy of better than 2 mm over a source to detector distance of 1 to 12
cm.
This method was experimentally validated shortly after by Nakano et al. [43] by placing
a single diamond detector at 12 positions on an anthropomorphic phantom that was
irradiated by a single HDR catheter. The source position was calculated by an iterative
method based upon a least square fit, which took into account detector responses
compromised by tissue inhomogeneity. As the accuracy of the localisation was highly
dependent on the knowledge of the catheter and detector positions on the phantom, it
was necessary to perform a CT scan to provide a frame of reference to the system. The
author remarks that measurements of dwell time could be feasible, depending upon
the measurement sampling frequency of the system used.
A method was proposed by Liu et al. [44] to use a mobile C-arm fluoroscopy machine
to image the check cable at the final dwell positions, prior to treating the patient.
Verifying by visual inspection, the authors remarked that the method is useful for
observing gross errors in dwell positions larger than 1 cm. This method images only
the check cable position at final dwell positions, giving no information about the actual
source positions during treatment.
A pretreatment check of the HDR source using film and a multi-slit phantom was
proposed by Kohr and Siebert [45]. By placing the HDR implant tubes directly on
top of the multi-slit phantom, dwell positions were determined to an accuracy of 0.45
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mm.
Three types of film were evaluated to determine the dwell position accuracy of the
HDR afterloader by Evans et al. [23]. The method used was to create a co-registered
image of the source autoradiograph, superimposed with a diagnostic x-ray of dummy
sources within the same applicator.
The idea of using of a flat panel detector for tracking the HDR source was described
by Song et al. [46]. The flat panel was coupled with an array of ball bearings, and used
their individual shadows to determine the source coordinates. The device was capable
of determining the position of the source with a mean difference of 0.7 mm with a
standard deviation of 1.5 mm. By using new devices with faster image acquisition,
and the development of an automated ball bearing shadow recognition software, source
tracking could be possible using this proof of concept.
Lambert was one of the first to investigate the use of plastic scintillator detectors
(PSD) coupled to optical fibres in HDR treatment verification [47]. The PSD system
was characterised in terms of depth dose response, angular and energy dependence and
the generation of Cerenkov and fibre fluorescence. The device tested was found to be
feasible for real time treatment verification and could be easily inserted into urinary
catheters.
The use of PSD for HDR pretreatment verification was tested by Kojima [48]. A single
HDR catheter was inserted into a hole centred inside of a 50×50×150 mm3 block of
organic plastic scintillator. The scintillation luminescence was digitally recorded using
a charge-coupled device camera system at a rate of 30 frames per second and with high
image resolution. The source position was determined from the image scintillation
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brightness distributions, with a precision of less than ± 1 mm. Source dwell and
transit times could also be determined with a timing resolution of 1/30 s.
Anderson et al. explored the use of carbon-doped aluminium oxide (Al2O3:C) crystals
for luminescence dosimetry in the application of in-body HDR brachytherapy verifica-
tion [49]. The highly sensitive crystal enabled a compact packaging design, that when
coupled to optical fibres, could be made to fit inside of standard brachytherapy ap-
plicators. The Al2O3:C crystal produced radioluminescent light spontaneously under
irradiation and could be used for real time dose rate monitoring. Also, by optically
stimulating the Al2O3:C crystal using a 532 nm 20 mW green laser, the accumulated
dose for the full treatment could be obtained while still inside the patient.
Batič et al. expanded the idea of pinhole imaging, using silicon pixelated pad detectors
instead of film [50]. Two catheters were fixed in a support structure with the detection
system at a fixed distance away in air. It offered the ability to reconstruct the source
position with a precision of about 5 mm from a source-to-pinhole distance in air of
40 cm. However, this precision is comparable to the distance between two dwelling
positions of the HDR source during treatment and was expected to arise from the
inaccurate alignment of the detectors with the pinholes. Although the readout of these
detectors allowed for reconstruction of source position in 1 s, giving the possibility of
tracking, there was no indication if the detection system was capable of measuring the
dwell time patterns of the source.
Rickey et al. [14] developed a quality check tool for HDR brachytherapy by combining
the use of radiochromic film and photodiodes and determining the dwell positions and
times in a fixed treatment tube. Readout of the four photodiode’s response occurred
with a timing resolution of 1 ms. Dwell position were reconstructed with an accuracy of
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0.5 mm by manual optical inspection and down to 0.2 mm by a digital post-processing
of the film. The authors state that this method allowed for the verification of the
position and dwell times of a single catheter in about 6 minutes.
PSD for in-vivo dosimetry and real-time monitoring of HDR treatments was investi-
gated by Therriault-Proulx et al. [51] and verified in a water phantom. Eleven catheters
were used for delivery of the HDR source, and an additional two were used to house
the PSD to mimic dosimetry at the rectum wall and inside the urethra. The mea-
sured doses and dose rates were compared to the values expected from the treatment
planning system and were able to determine position offsets of 5 mm. The hardware
limited the measurement to a maximum frequency of 10 Hz, and only dose rates for
dwell times greater than 5 s could be analysed.
The investigation into the use of Al2O3:C crystals for HDR in-vivo dosimetry was
continued by Kertzscher et al. [52]. By developing a statistical error criterion based
upon the agreement of the integral dose continuously measured and that simulated
by the treatment plan, source displacement errors of 5 mm and greater could be
detected. It was found that the statistical confidence in the comparisons between
measured and planned dose rates was dependent on the accuracy of the determined
dosimeter position.
Kertzscher et al. later addressed this shortcoming with a newer error adaptive detec-
tion algorithm that did not depend on an absolute prior detector position reconstruction [53].
The method compared dose rates for individual dwell positions measured by the
dosimeter with that simulated for multiple dosimeter positions. When a significant
difference was found between the measured dose rate and that simulated for a single
dosimeter position, the dose rates from the other simulated positions would be com-
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pared. If agreement was found with a new dosimeter position, then this was updated
for further use; if the disagreement was significant then the algorithm deems that a
treatment error was detected. This method was found to increase the sensitivity to
treatment errors, and could potentially be adapted to multiple dosimeters for increased
redundancy.
The use of commercial ion chamber arrays, designed for external beam radiotherapy,
was investigated by Manikandan et al. [54] for HDR source position verification by
placing the catheters directly on top of the device. The I’matriXX (IBA Dosimetry
GmbH, Germany) verified treatment dwell positions with a maximum error of 1.8 mm
for step sizes larger than 2 cm. It found that due to the large width of each ion
chamber of approximately 5.8 mm, the device displayed a volume averaging effect and
step sizes below 1 cm could not be resolved.
A novel in-body silicon pixellated detector was proposed for HDR brachytherapy by
Safavi-Naeini et al. [55] and for low dose rate (LDR) brachytherapy by Petasecca et
al. [56]. The concept device, named BrachyView, used the high spatial resolution
Medipix2 detector [57] coupled to a multi-pinhole tungsten collimator designed to
be inserted into the rectum, replacing the TRUS probe at the time of treatment.
Both applications used the images projected through each pinhole onto the detector
to determine source position, and for HDR treatments was shown to not cause dose
enhancement to the patient [58]. Monte Carlo simulations of the HDR 192Ir source
and various BrachyView collimator designs reported by Safavi-Naeini showed that the
maximum error in localisation would be 1.5 mm. Experimental verification of this
proof of concept has been researched and has been accepted for publication [59].
The use of an electric portal imaging device (EPID) for in-treatment monitoring was
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proposed by Smith et al. [60]. The source position was determined in three dimen-
sions from analysis of the shape of the measured radiation distribution and absolute
response. The system was able to determine the source x and y coordinates with an
accuracy of 0.5 mm for source to detector distance of up to 150 mm. The determina-
tion of the source to detector distance was found to be a approximately ± 0.1 mm at
50 mm distance, and up to ± 2 mm at 150 mm.
Wang et al. and Pittet et al. proposed the use of GaN scintillating probes for in
phantom pretreatment verification [38, 61]. The position of the HDR source inside a
single catheter was determined from the comparison of the measured response of two
probes and TG-43 dose rate calculations. The differences between the measured and
planned positions were found to be lower than 1 mm, with dwell time differences found
to be within 0.1 s, the same as the temporal resolution of the acquisition system used.
Jursinic devised a way to perform pretreatment quality assurance using a single p-
type semiconductor diode readout with an electrometer [62]. The diode was fixed into
Styrofoam, close to the boundary of a 6 mm Plexiglas slab. A single straight catheter
and ring applicator were tested by placing them on top of the Plexiglas, aligning the
catheter over the diode and the ring centred at the diode. The source position was
determined with an accuracy equal to or less than ± 0.3 mm for the ring applicator
and straight catheter. Checks of the temporal accuracy of the HDR afterloader were
performed and found to have an accuracy of 0.3% using this device.
Two commercial devices have been developed by Mick Radio-Nuclear Instruments
for HDR QA. The PermaDoc GC Phantom allows for the insertion of a single HDR
catheter into the device, where the source exposes its position, as well as centime-
tre markers, onto gafchromic film. This solution verifies one catheter at a time and
2.9. Measurements of the HDR source transit time 36
would require digital post processing to determine an accurate position. The Mul-
tiDoc Phantom, developed by Mick Radio-Nuclear Instruments, allows for up to 21
catheters inserted into a phantom, where the source can be seen through the catheter,
above the phantom. Next to each catheter insert are positional markings in 1 mm
increments, and the source dwelling and timing is captured by a high resolution video
camera above the phantom. While capable of source position and timing of up to 21
catheters, the system relies heavily on the user to perform verification by watching
and analysing the video recording.
2.9 Measurements of the HDR source transit time
Transit dose is defined as the additional dose delivered while the source is in transit, as
seen in Figure 2.7. Currently, only the dwelling components of the treatment plan are
used to calculate the total dose by the treatment planning software. However, as the
HDR afterloader moves the source at a finite speed and the 192Ir source is continuously
decaying, there is a dose delivered to the patient not taken into account by the TPS.
Direct measurements performed by Bastin et al. using thermoluminescence dosimetry
showed that the transit dose could exceed a few hundred cGy for some treatment
scenarios [63]. By not factoring in this additional dose when using high activity sources
and short dwell times, significant error can be introduced in dose calculations.
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Figure 2.7: The transit motion and dose delivered to an arbitrary point P.
In the literature, methods of calculating the transit dose is generally based upon a
determination of the average source speed during transit, or by assuming a constant
acceleration phase, a constant maximum speed and a constant deceleration. Nucle-
tron, the manufacturer of the tested afterloaders, claims that the maximum speed of
the source is 50 cm/s, and uses this value to perform compensations during delivery.
The average source speeds reported in the literature vary substantially, and a summary
can be found in Table 2.2.
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Interdwell Average source speed (cm/s)
distance (mm) aBastin bHoudek cSahoo dWong eFonseca fEspinoza
2.5 23 22.7 — 5.4 ± 2.3 32.8 ± 2.7 12.8 ± 0.3
5 25.5 27.1 33.3 ± 11 7.2 ± 1.6 45.8 ± 2.6 17.5 ± 0.3
10 — 30.3 50 ± 50 23.3 ± 7.3 34.9 ± 0.9 24.7 ± 0.3
20 — 32.3 80 ± 32 — — 31.8 ± 1
30 — 32.7 60 ± 30 — — 33.3 ± 0.9
50 — 33.1 43.5 ± 11.3 — 32 ± 0.2 38.6 ± 0.4
Table 2.2: Summary of the average source speeds based upon measured transit times
reported in the literature for varied interdwell distances. All values were obtained
using a Nucletron afterloader (Nucletron, an Elekta company, Elekta AB, Stockholm,
Sweden). Not all uncertainties were reported. aBastin et al. [63], bHoudek et al. [64],
cSahoo [65], dWong et al. [66], eFonseca et al. [67] and fEspinoza et al. [16].
Houdek el al developed a mathematical formalisation of the dose received at a point
by the source in transit [64]. An estimation of the transit time was performed using an
oscilloscope to measure the pulse generator of the stepping motor of the afterloader.
Although the transit dose component was not measured, calculations were performed
to determine the effect of the transit dose on a plan using the measured source speeds.
Measurements of the transit times were performed by Sahoo [65] using an ionisation
chamber and a precision electrometer to measure the charge generated during the
movement of the HDR source. The average source speed was determined over a range
of step sizes, from 5 mm to 100 mm. However, due to the error in charge measurement,
time error in the afterloader and the transit time correction by the afterloader, up to
100% uncertainty was recorded for some average speeds.
Wong et al. used a video camera to film the movement of the source in a flexible
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transparent catheter placed next to digital stopwatch with a timing resolution of 0.01
s [66]. A maximum average transit speed was determined to be 52.9 ± 1.5 cm/s for
the travelled distance of 99.5 cm, however, by assuming a constant acceleration and
deceleration phase at one-fifteenth the distance for each, the average source speed was
computed to be 46.7 cm/s.
Using an optical fibre system to detect the radiation generated by the moving HDR
source, Minamisawa et al. were able to calculate the instantaneous and average source
speed [68]. By placing two optical fibres at set distances apart, and close to the HDR
catheter, the Cerenkov light induced by the moving HDR source was used to assess the
transit time across that distance. The optical fibres were connected to a photomulti-
plier tube that converted the light to an electrical signal and was directly measured by
an oscilloscope. By fixing the optical fibres spacing to 1 cm, the deceleration profile of
the HDR source was determined, as well as the average speeds over various interdwell
distances. The authors concluded that the source undergoes constant acceleration and
deceleration, of approximately 113 cm/s2.
The transit dose of an HDR unit was quantified by Fonseca et al. [69], based upon
calculations of the instantaneous source speed and a Monte Carlo (MCNP5) simu-
lated transit dose profile. The instantaneous source speed, measured by the optical
fibre based system reported by Minamisawa et al. [68], was used to give weighting to
the simulated transit dose and allow for an accurate calculation of transit dose values.
The results were verified experimentally using radiochromic film, and showed that the
transit component can be significant, reaching up to a few hundred cGy per applica-
tion. Fonseca et al. later determined the total transit dose to the patient using this
method for two gynaecological and two prostate cases, each having a different number
of catheters and locations [70].
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Fonseca et al. then used a high speed video camera to measure the source motion
through the position check ruler [67]. The video camera was able to film at 960 fps, with
a verified timing resolution of 1.04 ± 0.01 ms, and the source position was analysed
frame-by-frame using MATLAB 8.0 (MathWorks, Inc., Natick, MA). It was seen that
source motion was changing speed periodically, as it moved from dwell position to dwell
position. The author concluded that the accelerating and decelerating were unable to
be seen in the aforementioned studies due to the timing resolutions used.
The average source speed was investigated by the author as part of this research, using
a single silicon diode detector and fast electrometer [16]. The sensor was readout by
a single channel fast electrometer named X-Tream, which is designed as a dosimetry
system for microbeam radiation therapy QA [71], and is characterised by its high
dynamic range (∼ 105) and high sampling rate (1 MHz). Using high timing resolution
of the system, the transit time was analysed by considering the time needed for the
source response to become constant after stepping. Information about the source
position was not known as the system used only one detector.
2.10 Silicon detectors for quality assurance
Silicon detectors have been predominantly used for nuclear spectroscopy since the
1960s and, with the development of manufacturing technology, have found application
in the dosimetry of clinical radiation treatments [72–74]. Silicon has characteristics
that are very attractive for use as a dosimeter, as they can be used to measure dose
or dose rate in real time, as a substitute to ionisation chambers.
The average energy for creating an electron-hole pair in silicon is 3.6 eV, approxi-
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mately 10 times smaller than that for gases used in ionisation chambers. Coupled
with a higher density of 2.33 g/cm3, the result is a radiation sensitivity approximately
18,000 times higher than an ionisation chamber of the same volume. As a result, the
measurement volume of the detector can be small and well defined, leading to a good
spatial resolution [75,76]. Silicon detectors have other favourable features such as the
ability to operate at room temperature, are mechanically stable and need a low or no
bias voltage.
However, there are two main limitations when considering silicon as a material for
radiation detectors. Due to the increased interaction cross section of the photoelectric
effect in silicon relative to water in the keV energy range, illustrated in Figure 2.8 a),
silicon exhibits a greater sensitivity to low energy photons, which must be taken into
account when performing dosimetry in this energy range.
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Figure 2.8: Comparison of µen/ρ for Water and Silicon. Data obtain from NIST
database [77].
Figure 2.8 b) shows the ratio of the mass energy-absorption coefficients, µen/ρ, of
silicon to water over the range of 1 - 600 keV, with the data obtained from the U.S.
National Institute of Standards and Technology (NIST) database of x-ray mass at-
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tenuation coefficients [77]. The mass energy-absorption coefficients is an important
quantity for the determination of energy deposition by photons, and the ratio can be
used to calculate dose in different mediums. It is important to note that between the 1
- 100 keV photon energy range, there is an approximately 7.5× increase in sensitivity,
and that over energy ranges of 150 keV, the difference is less pronounced and silicon is
said to be water equivalent. This over sensitivity of a silicon detector can be mitigated
by the choice of application in specific photon energy ranges, by the packing of the
detector and by the use of low energy photon shielding materials.
The second limitation is that damage to the detector that occurs when dose is ac-
cumulated by the detector, resulting in a decreased sensitivity, increased noise and a
decrease in the carrier mobility and its lifetime [78]. The radiation damage is known
to increase the current when the diode is reverse biased, known as the leakage current,
and is due to radiation induced defects within the bulk silicon and the silicon oxide
interfaces. By operating the detector in passive mode, this leakage current can be
reduced, and the reduction in sensitivity can be mitigated by detector design [79].
Silicon diode detector theory
The physics of the p-n semiconductors is fundamental to the use of a silicon diode
as a radiation detector [80]. P-type and n-type semiconductors are created by the
controlled addition of impurities from either group III or group V elements to high
purity semiconductor crystals, known as intrinsic semiconductors, in a process known
as doping. N-type silicon is made by introducing a donor atom into a crystal, usu-
ally phosphorus or arsenic, while an acceptor atom is introduced, such as boron, to
obtain p-type silicon. For n-type silicon, the majority carriers are electrons and the
minority carriers are holes, while for p-type, the majority are holes and the minority
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are electrons. The energy level structures for the intrinsic, p-type and n-type silicon
are shown in Figure 2.9.
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Figure 2.9: The electron energy band diagram for a) intrinsic, b) p-type and c) n-type
silicon. Electrons and holes are displayed as black and white circles, respectively.
In each of the three illustrations, the valence and conduction bands can be seen, with
their respective energies, Ev and Ec. The valence band represents the electrons bound
to the highest energy orbitals of the atoms in the crystal, while the conduction band
represents the possible energy states of electrons that are free to migrate throughout
the crystal and contribute to electrical conduction. Electrons that are excited ther-
mally or otherwise can overcome the energy gap between the valence and conduction
bands, Eg, leaving a hole in the valence band. The Fermi level, EF , is between the
valence and conduction bands for the intrinsic semiconductor, and is the top electron
energy state for the collection of energy levels at absolute zero temperature.
Acceptor atoms have one less electron in the outer shell and changes the energy level
of p-type silicon by introducing acceptor states, EA, which shifts the Fermi level closer
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to the valence band. This allows for extra holes to be in the acceptor states that
can be filled by excited electrons from the valence band, leaving mobile holes, which
adds to electrical conduction. Conversely, donor atoms have one additional electron in
the outer shell and changes the energy level structure of n-type silicon by introducing
donor states, ED, which shifts the Fermi level closer to the conduction band. These
extra electrons fill the donor states, and can be easily excited into the conduction band.
By combining the p-type and n-type semiconductor materials, semiconductor devices
can be created. The most basic combination of these materials is the p-n diode.
n-type
p-type
Depletion
Region
Figure 2.10: The movement of electrons and holes to form the p-n junction depletion
region.
The p-n junction is defined as the boundary between the p-type and n-type semicon-
ductor material. At the junction boundary, there exists a region that is almost free of
movable charge carriers, known as the depletion region. This is formed by the diffusion
of electrons from the n-type towards the p-type region, leaving positively charged ions
at the n-type material, and the movement of holes from the p-type to the n-type,
leaving negatively charged ions, seen in Figure 2.10. The separation of positively and
negatively charged ions generates a strong electric field across the depletion region,
and prevents the further diffusion of electrons and holes.
When an ionising particle passes through the diode, energy is deposited through the
creation of electron-hole pairs along the particle’s path, seen in Figure 2.11. If the
2.10. Silicon detectors for quality assurance 45
particle track is through the p-n junction, the electron-hole pairs are separated and
swept by the electric field in the depletion region. The electrons are accelerated towards
the n-type junction of the detector, while the holes move towards the p-type.
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Figure 2.11: Electron-hole pairs created along a radiation particle track inside of a p-n
diode.
The two main modes for the operation of radiation detectors are pulse mode and cur-
rent mode [72]. Pulse mode operation, also known as spectroscopy mode, is when the
radiation detector system is designed to record each individual quantum of radiation
that interacts with the detector. When considering high event rates, like in HDR
brachytherapy, it could be impractical to operate the detector in this mode, as in-
dividual radiation interactions may not be distinguished. By designing the readout
electronics for use in current mode, the average current induced over many radiation
interactions can be recorded and used to determine the dose rate. The resulting ra-
diation induced current can be measured by an electrometer, where the current and
the total charge are proportional to the dose rate and total absorbed dose in silicon,
respectively.
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2.11 Conclusion
Prostate cancer has one of the highest occurrence rates for males in Australia, with a
projected 25,000 cases being diagnosed each year by 2020. High dose rate brachyther-
apy, typically used in combination with other methods, is one of the more common
options to treat this disease. The short treatment involves remotely controlling the
temporary placement of the small, highly active radiation source directly into the
tumour, until the large prescribed dose distribution is achieved.
Accurate treatment delivery relies on the exact execution of the patient plan. This
means that the remote afterloader should move the HDR source with high precision
in its positioning and timing.
Whilst methods are being developed to verify the quality of a treatment delivery, they
can use bulky and expensive equipment, and not provide a complete picture of the
delivery. There is currently no comprehensive method to verify the afterloader delivery
of the plan, both pretreatment and in-vivo.
Silicon detector technology has the potential to fill this gap in verification systems.
Due to its desirable qualities, such as the ability to perform measurements in real-time,
its high temporal response and strong radiation response, they have been selected to
be used for the development of a quality assurance system in this work.
Chapter 3
Description of the proposed
instrumentation
The previous chapter reviewed the current technology used in high dose rate brachyther-
apy reported in the literature, and concluded with silicon diode detectors being a very
attractive candidate for the development of a HDR brachytherapy quality assurance
system. This chapter goes on to describe the technology proposed for the verification
of treatment delivery, describing from the single detector element to the array of ele-
ments, the prototype phantom design, electronics system and graphical user interface
that has been designed and implemented.
3.1 The "Magic Plate"
The Centre for Medical Radiation Physics (CMRP) at the University of Wollongong
has designed a two-dimensional (2D) detector array, named "Magic Plate" (MP) [81].
It features 121 p-type silicon epitaxial diodes embedded in a 0.6 mm Kapton carrier
in an 11×11 array, Figure 3.1. Each epitaxial diode has been connected to the MP
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flexible carrier, which consists of a thin polyamide supporting substrate with a thin,
chemically deposited aluminium layer tab bonded to the detector’s pads and to the
kapton carrier’s copper tracks [82].
The MP uses two SCSI-2 connectors, with 68 channels each connector, to interface
with the readout electronics. This makes the MP modular, and can be it interchanged
with different versions of the front-end data acquisition systems. To minimise current
generated in the detector and the kapton carrier’s tracks, the entire MP was covered
with 70 µm of aluminium tape, which was then connected via wire to the AFE DAQ
system electrical ground. This was done to shield the detector from interferences from
external electromagnetic fields.
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Figure 3.1: The "Magic Plate" detector.
The silicon diodes are designed and developed at the CMRP and fabricated at the
foundry SPA-BIT (Ukraine). Each detector is manufactured on a 50 µm thick p-type
(100 ohm·cm) silicon epitaxial layer, grown onto a 375 um thick (0.001 omh·cm) silicon
substrate. The sensitive area of the diode is 0.6×0.6 mm2 and is defined by an boron
ion-implanted junction.
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Figure 3.2: The epitaxial diode. Illustration not to scale.
By manufacturing a detector on a p-type substrate and with active region dimensions
smaller than the minority carrier diffusion length, it is expected that the sensitivity
will remain largely stable and independent of accumulated dose. Simulations of the
epitaxial diode using Sentaurus TCAD (Synopsys, Bulgaria) have shown that the de-
pletion layer thickness remains independent of the accumulated dose due to photon
damage [83]. It was shown that there was an increase in the sensitive area of the detec-
tor with increased accumulated dose, resulting in a larger sensitivity of the detector,
which plateaued at 40 kGy dose in water. To minimise the leakage current generated,
each MP detector is configured to be in passive mode, that is 0 V bias exists between
the p+ and n+ junctions.
The MP detector and electronics response was normalised to be constant across all
channels when inside a uniform radiation field. This was performed using a 20×20 cm2
photon field from a 6 MV linear accelerator (LINAC) at a source-to-surface distance
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of 100 cm in a 30×30×30 cm3 Solid Water R© (SW) phantom. The MP was placed at a
depth of 10 cm, where the photon field has a flat dose profile, verified regularly using
ion chamber measurements as part of the LINAC’s quality checks. Reproducibility of
the diodes response over a period of 64 days were found to be approximately 2.1% [81].
A characterisation of the "Magic Plate" was performed to assess the energy depen-
dence, dose rate dependence and dose linearity [81]. The energy dependence was
characterised using an orthovoltage therapy machine with nominal energies of 75 –
250 kV, and 6 and 10 MV photons. It was found that the "Magic Plate" displayed a
significant energy dependence, with a maximum of 7× at the lowest equivalent photon
energy of approximately 31 keV when compared to the 6 MV response. It is expected
that this energy dependence, coupled with the low energy 192Ir spectrum, will make
it extremely difficult to perform dosimetry with this system.
The dose rate response can be derived from the dose per pulse characterisation, where
a range of dose per pulses were achieved by varying the source-to-surface distance,
isolating the effect of the changes of the 6 MV beam spectrum on the measurement.
The "Magic Plate" showed a flat dose rate response over an equivalent dose rate of
3 – 130 Gy/h, with lower dose rates not possible to be evaluated due to limitations
in the sensitivity of the older generation data acquisition system used. It is expected
that the "Magic Plate" should not have a dose rate dependence when used in HDR
brachytherapy testing. The dose linearity was found to be linear for the measured
dose range of 5 – 1000 cGy (r2 = 1).
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3.2 The "Magic Phantom" prototype
For pretreatment plan verification, a prototype phantom was designed to house the MP
detector array and up to 20 HDR treatment plastic catheters. The prototype casing,
named "Magic Phantom" (MPh), is made of Polymethylmethacrylate (PMMA) slabs.
This was selected due to the availability of material and optical transparency, which
assisted the of aligning the detector and catheters in the phantom. An illustration of
the "Magic Phantom" is seen in Figure 3.3. Solid Water R© slabs are placed both above
and below the "Magic Phantom" to make a total phantom size of 30×30×30 cm3. A
characterisation of the total amount of backscatter material needed is performed in
Chapter 4.
Figure 3.3: Sketch of the "Magic Plate" inside the "Magic Phantom".
The phantom is made up of three slabs of PMMA, each 30×30×1 cm3, with the
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MP 10×10 cm2 detector field of view (FOV) positioned in the centre of the "Magic
Phantom". The top and bottom layers have ten 15×2×2 mm3 channels machined
into the boundary of the centre slab to allow for the insertion of up to 20 HDR plastic
catheters. These trenches are aligned so that the bottom row of catheters is positioned
directly below the columns of the detector array and the above row of catheters is
positioned in between the detector columns, as seen in Figure 3.4.
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Figure 3.4: Illustration of catheter channels with respect to the "Magic Plate".
White squares represent diode positions relative to catheters, with the two rows of
catheters above (black) and below (grey). The left figure shows a top view of the
catheters inserted into the MPh with respect to the detectors position, and the x and
y-coordinate origin on a corner detector, as indicated by a cross. The right figure
shows the side view of the MPh with the catheters numbered 1 to 20. Twenty plastic
5F ProGuide Sharp catheters (Nucletron, an Elekta company, Elekta AB, Stockholm,
Sweden) of equal length were inserted into the MPh and individually connected to the
remote afterloader using 1 m transfer tubes, as seen in Figure 3.5.
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Figure 3.5: Diagram of the MPh system when used in pretreatment verification mode.
3.3 The AFE DAQ system
The analog front end (AFE) data acquisition (DAQ) system [84,85] uses the commer-
cial electrometer AFE0064 manufactured by Texas Instruments (Texas Instruments,
Dallas, United States of America). The AFE0064 was originally developed to readout
flat panels for portable imaging devices, but has been adapted by the CMRP to be
the electrometer for the in-house developed DAQ system. It features 64 individual in-
tegrator circuits for each channel, with a selectable global sensitivity range of charge.
The charge full scale can range from 0.13 pC up to 9.6 pC in eight steps. A simplified
schematic of a single channel, seen in Figure 3.6, is useful for understanding the basic
principle of operation of the AFE0064 chip.
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Figure 3.6: Integrator schematic for each AFE channel.
Each channel has a reset switch, which reverts the integrator output to the reset-level.
During the acquisition phase the reset switch is opened, and the current generated
from the detector, due to radiation and the leakage current, charges the capacitor
on the feedback loop of the amplifier. This produces an output voltage (V) on the
amplifier which is proportional to the total amount of charge collected (C) and the
size of the capacitor (C), (Q = CV ). The output voltage is measured at the end of
the acquisition phase; this measurement is called the signal sample. The reset phase
is then initiated by closing the reset switch. At the end of this phase, the output
voltage is measured again; this measurement gives the reset sample. Once both signal
and reset samples have been obtained for each channel, the difference between them
is sampled by a 16 bit analogue-to-digital converter (ADC) in a differential format.
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Figure 3.7: The AFE Readout chips.
The range of sensitivity of the AFE0064 is selected by the user and the differential
output is set to be between ± 1.4 V, regardless of the chosen range. The output of the
ADC is expressed as a percentage of the full scale of the measurable charge for that
selected range. The ADC data is then digitally transferred to the Field Programmable
Gate Array (FPGA) which stores the information and handles data transfer to the
PC. This system has a dead time of approximately 70 µs per measurement, to allow
for data-transfer and the resetting of the integration capacitors.
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Figure 3.8: The FPGA master board
The FPGA is used to handle the communication between the electronics and the PC,
master the timing of the AFE0064 boards and control the acquisitions
reset phases. Communication between the FPGA and PC happens over the standard
Universal Serial Bus (USB) link. Once the measurement parameters and commands
are set by the user and transmitted to the FPGA, the AFE0064 begins the measure-
ment and integrates all input channels simultaneously.
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3.4 BrachyPix – the "Magic Plate" software toolkit
The graphical user interface (GUI), "BrachyPix", was designed for the purpose of this
research. It has been compiled under the C++ developing suite Qt rev5.3.1 and is used
to manage the communication with the AFE system during acquisition and perform
real time and post-processing analysis. The interface is used to perform the HDR
source tracking algorithm and an automated determination of the dwell positions and
times, as described in Chapter 5.
Figure 3.9: BrachyPix – frame-by-frame and integral response.
When the AFE DAQ system is connected, BrachyPix opens the communication to the
FPGA over the USB 2.0 connection. When the connection is established, an instruc-
tion set is communicated to the FPGA to program the chip. The user is able to adjust
the measurement parameters, such as: integration time, the total acquisition time,
the AFE sensitivity range and the frequency of measurement. When measurement is
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initialised through BrachyPix, these parameters are sent to the AFE, with the start
signal, to begin the acquisition.
Raw data is downloaded from the FPGA memory stack, with a maximum data transfer
speed of 48 Mb/s, and is saved to a file on the computer storage. During measurement,
the GUI decodes a single packet of the raw data to update the 2D detector response
colour map, and calculate the source position at 100 frames per second. The system
is capable of running at a minimum integration time of 14 µs and up to a stable
maximum acquisition frequency of 10 kHz. The maximum integration time has been
found to be 9920 µs, with an associated minimum acquisition frequency of 100 Hz.
Figure 3.10: BrachyPix – TPS and MPh catheter gamma analysis
The integration time, frequency and range are selected based upon the test performed.
Typically, for pretreatment plan verification, performed in Chapters 8 and 9, the
system is set to run at 100-200 µs integration time and at 1 kHz acquisition frequency.
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As each measurement sample generates 769 bytes of data, a 15 minute acquisition will
generate a file of approximately 660 MB, without using data compression. For the in-
vivo feasibility testing (Chapter 10), the integration time was set to 9920 µs and 100
Hz to improve the signal-to-noise ratio, at a cost to decreasing the timing resolution.
Measurements with high temporal resolution, performed at 5 – 10 kHz, can be used
to determine the source motion profile (Chapter 7), but result in larger data sets per
measurement. Adjustment of the measurement parameters, based on the experiment
performed, can be used to achieve a balance between the timing resolution and total
amount of data generated.
Figure 3.11: BrachyPix – TPS, MPh measured and transit dose maps.
As described later in this thesis, methods for the determination of the source position
in each measurement frame and the dwell positions and times were developed and
implemented into the BrachyPix post-processing analysis. The GUI features the ability
to read DICOM files generated by the TPS, and to extract the planned source dwell
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positions and times, relative to the catheter tip and the coordinate system used. The
comparison between measured and planned dwell positions and times is displayed
within the GUI, Figures 3.10 and 3.11.
BrachyPix also features a dose calculation engine based upon the TG-43U1 protocol.
It uses 192Ir source parameters for both the Flexisource and microSelectron v.2., cal-
culated using Monte Carlo methods by Granero et al. [86] and Taylor et al. [28]. Dose
points calculated by the TPS and saved to the DICOM file were used for comparison
of the values calculated by BrachyPix.
3.5 Gafchromic EBT3 film
Gafchromic EBT3 film (Ashland ISP Advanced Materials, USA) lot #A07151302 was
used to verify the dose calculated by the Nucletron ONCENTRA R© TPS and BrachyPix
in Chapters 6 and 8. Due to the manufacturers stated dose range of "1 cGy to > 40
Gy", the tested dose range of up to 90 Gy [87] and relatively weak energy dependence
for energies as low as 50 keV [88,89], the use of Gafchromic EBT3 appears well suited
for use in 192Ir HDR brachytherapy dosimetry and plan verification.
EBT3 film calibration
The film was calibrated by exposing five 10×10 cm2 pieces to the HDR 192Ir source.
The MPh was disassembled and the top layer with catheter trenches was placed in a
30×30×30 cm3 Solid Water R© stack. A single piece of film was placed at the centre of
the stack, and a single catheter was inserted into a trench directly over the centre of the
film, at an approximate source-to-film distance of 16 mm. Nucletron ONCENTRA R©
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TPS was used to calculate the necessary time to deliver the required dose to the film,
with the 5 pieces of film irradiated to 100, 200, 400, 600 and 1000 cGy using a single
dwell position.
The film was pre-scanned and post-irradiation scanned using a 48-bit RGB transmis-
sion film scanner, the EPSON 10000XL, at a resolution of 300 dots per inch (DPI).
No colour or sharpness corrections were applied and care was made to orientate and
position the film consistently in scanner. Approximately 72 hours had passed between
film irradiation and post-scanning to ensure the film response had stabilised. The
calibration films were scanned and the image files were measured using IMAGEJ (ver-
sion 1.47v). Six consecutive scans were performed for each piece of film to stabilise
the performance of the scanner, and achieve consistency on the last three used for
analysis.
Using IMAGEJ, a macro was created to select a circular region of interest with a
diameter of 30 pixels (2.54 mm) that was moved around the image of the irradiation
on the film until the minimum pixel value was detected, signifying the largest change
in optical density. The net optical density (netOD) was determined for a piece of film
exposed to a dose Di as
netOD(Di) = log10
(
I0
I(Di)
)
(3.1)
where I0 is equal to the average mean pixel value of the pre-scans and I is the average
mean pixel value of the post-irradiated film. The dose response curves are plotted in
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Figure 3.12. Uncertainties of the net optical density were calculated using
σnetOD(Di) =
1
loge 10
√√√√(σI0
I0
)2
+
(
σI(Di)
I(Di)
)2
(3.2)
where σI0 and σI(Di) are the standard deviation of the pixel value of the pre-scan film
and post-irradiated film, respectively.
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Figure 3.12: Dose response curves for the 192Ir energy spectrum in red, green, blue
channels.
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Figure 3.13: Calibration curve for the red channel using a 2nd order polynomial fit.
It is clear that for the 192Ir photon energy range and the dose delivered, the red channel
gives the largest change in optical density and, as such, was chosen for the dosimetry
calibrations. In Figure 3.13, a 2nd order polynomial was used to fit the net optical
density to absorbed dose D (cGy), by
Dfit = a× netOD + b× netOD2 (3.3)
where a = 946.7 ± 53.9 cGy and b = 5723.3 ± 188.4 cGy. The uncertainty in obtaining
the dose measured at each point of interest was determined by
σD(%) =
√
(netOD × σa)2 + (netOD × σb)2 + (a+ 2× b× netOD)2 × σnetOD)2
Dfit
×100
(3.4)
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EBT3 dose uncertainty
Sources of uncertainty and their estimated contributions are listed in Table 3.1. The
average calibrated dose uncertainty, calculated using the above equation, was 3.5% (1
S.D). The total contribution of the uncertainty based upon the listed sources was 6.1%
(1 S.D).
Uncertainty components Type A (%) Type B (%)
Source-to-film positioning
- Calibration (16 mm) 1.3
- Measurement (6 mm) 3.3
Scanner homogeneity 0.2
Scanner reproducibility 0.1
netOD measurement reproducibility 1.1
Calibration curve 3.5
TPS dose calculations including Sk Measurements [90] 3.4
Total uncertainty (k=1) 6.1
Table 3.1: EBT3 film dose calculations sources of uncertainty.
3.6 Discussion and conclusion
This chapter provides a description of the 2D detector, the "Magic Plate"and the
pretreatment verification phantom, the "Magic Phantom". The AFE DAQ system
that was connected to the MP was used to sample the measured generated integrated
charge and relay the data to BrachyPix, the software suite. BrachyPix was designed
to provide an interface between the user and the electronics system, allowing the user
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to set the required measurement parameters, start and stop the measurement and
perform the HDR source tracking, both in real time and in post-processing. EBT3
film was also introduced, with the dose calibration procedure presented, as it appears
in further chapters in this thesis. The following chapter details the feasibility tests
performed to characterise the use of the MP and AFE systems for use in HDR quality
assurance.
Chapter 4
The feasibility of the "Magic Plate"
for HDR Quality Assurance
This chapter presents the preliminary study performed to determine the suitability
of the MP detector for use in HDR brachytherapy quality assurance1. The study
assessed the baseline electronic noise measured by MP, the changing response of the
MP at various distances from the HDR source and the angular dependence of the MP
detectors.
The baseline noise was characterised for changing the integration times in order to
investigate their effect during the pretreatment and in-vivo measurements. By varying
the distance of the MP detector from the HDR source, the relative response of the
MP could be compared to calculations made using the The TG-43U1 protocol, to
determine the expected response and limitations of measurements for in-vivo. The
response of the MP detector at different angles to the HDR source was investigated to
1 Part of this chapter has been published in Medical Physics:
A. Espinoza, B. Beeksma, M. Petasecca, I. Fuduli, C. Porumb, D. Cutajar, S. Corde, M. Jackson,
M. L. F. Lerch, and A. B. Rosenfeld, "The feasibility study and characterization of a two-dimensional
diode array in "magic phantom" for high dose rate brachytherapy quality assurance.," Medical Physics,
vol. 40, p. 111702, Nov. 2013.
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learn the suitable orientation of the detector and compensation factors that may need
to be applied.
Measurements were performed using the Nucletron microSelectron R© mHDR-v.2. after-
loader (Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden) at the Prince
of Wales Hospital, Sydney.
4.1 Electronic noise of the "Magic Plate" system
The MP will be used to determine the HDR source position, based on the measured
charge generated in each detector within a set integration period. The electronic noise
of the MP and the AFE DAQ system was characterised to ensure that there would
be a minimal influence on measurements with the 192Ir source. Due to the size of the
sensitive volume of the MP detector element and the reduced radiation intensity at
large distances, it is expected that the integrated current in the MP will be relatively
low for in-vivo feasibility measurements and approach a similar order of magnitude as
the baseline electronic noise.
Methods
The MP detector was placed into the MPh, inside the HDR treatment suite at the
Prince of Wales Hospital. The baseline of the MP system per channel was defined
as the generated current measured with minimised external radio-frequency influences
and from the HDR source itself. Thus, during the measurement, light sources inside
the room that were not needed were switched off and the 192Ir source was secured inside
the afterloader safe. For each 30 s measurement, the MP integration time was varied
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from 14 µs up to 9920 µs. The sampling frequency of each acquisition with integration
times between 14 and 920 µs was set to 1 kHz. For integration times greater than 920
µs, 100 Hz was used for the sampling frequency. The induced current in the MP and
the AFE DAQ system was analysed to determine the sources of noise in the system.
Results
The average baseline for each AFE channel when connected to the MP is shown in
Figure 4.1. Each error bar shows the variation of that channel’s response (2 S.D) over
30 s acquisition time. The maximum integrated current was found to be below 12.5
pA for all input channels and integration times. The average integrated current across
all MP detectors and AFE channels was found to decrease with increasing integration
time, with values of approximately 1.26 ± 3.19 pA and 1.15 ± 2.93 pA (2 S.D) for the
100 µs and 9920 µs integration time, respectively.
It can, however, be distinctly seen that channels 0-63, found on the AFE chip 1, had a
much larger baseline when compared to Channels 64-112 on the AFE chip 2. Whilst
each AFE chip is connected to the same electronic circuit on the readout board, the
placement of the individual AFE chips, the DC voltage regulators and the electrical
tracks position and orientation, in respect to the external noise source, could influence
the variation between the two chips.
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Figure 4.1: Baseline noise generated in the "Magic Plate" and the AFE DAQ system.
The response of a single AFE channel – Channel 61, for the 100 µs integration time
and 1 kHz acquisition frequency is shown in Figure 4.2. This channel has a relatively
constant response of an average of 7.96 ± 1.06 pA (2 S.D) over the duration of the
measurement. Assuming that the noise level of each MP detector did not vary during
measurements while using the 192Ir source, a baseline subtraction was performed to
ensure that the integrated current measured was strictly due to the HDR source.
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Figure 4.2: Baseline noise generated for Channel 61.
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Figure 4.3: Fast Fourier transformation of Channel 61 response.
The sources of the noise were analysed using a Fast Fourier Transformation (FFT) to
determine the frequency components of the channel response over time. Figure 4.3
shows that the majority of the spectrum is of a constant amplitude over the frequency
range, which could be due to thermal noise from the MP detectors and the AFE DAQ
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system. However, there are noticeable peaks at 50 and 150 Hz. This implies that the
MP and AFE system are sensitive to the main power lines, which has a frequency of
50 Hz, used to power the system. The 150 Hz is most likely a harmonic of the power
lines frequency.
4.2 The effect of backscatter material on the "Magic
Plate" response
It is necessary to determine the appropriate level of backscatter material that can be
used to simulate an infinite water volume, which is typically assumed by the TPS and
the TG-43U1 protocol. It is expected that with increasing backscatter material, the
response of the MP will increase.
Methods
The MPh was placed vertically onto a flat piece of dense foam, with equal thickness
of SW placed on each side of the phantom, Figure 4.4. This set-up kept the MPh
perpendicular to the treatment coach, and attempted to keep the MP away from
scattering material that could adversely affect the results. Although there would be
scattering of photons inside the treatment room, such as from the treatment devices
and the patient coach, this method aimed to minimise these effects.
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Figure 4.4: Backscatter test experimental set-up.
The MPh was configured so that the top and bottom row of catheters were directly
next to each other. The HDR source was then programmed to dwell for 2 s at po-
sitions directly above and below the central MP detector. This measurement was
performed with SW thickness from 0 – 120 mm on each side of the vertical MPh. The
0 cm backscatter thickness measurement used no SW pieces, but considered only the
response due to the MPh itself (3 cm thickness in total).
At the time of measurement, it was not possible to obtain the final additional 3 cm
of SW to create a 30×30×30 cm3 phantom due to constraints in the clinic. The
measurement was repeated 3 times per thickness, and the average integral response
for the central detector from both dwell positions were calculated and were used to
evaluate the change in response.
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Results
The increase in the detector response with backscatter thickness, normalised to 0 cm
SW, is shown in Figure 4.5. Errors were determined from the 2 S.D of the measured
integral response. It was seen that the central detector response continues to increase
with SW from 100 ± 0.29% to 103.94 ± 0.43% at the largest amount of backscatter
material measured.
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Figure 4.5: The "Magic Plate"detector response with increasing backscatter material.
The increase in detector response is largest between the 0 and 100 mm of SW on both
sides of the MPh. The change in response begins to decrease with increasing amounts of
backscatter material, and based on the trend it is estimated that backscatter amounts
greater than 50 mm each side will result in a less than 1% increase in integral response.
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4.3 Source-to-detector distance dose measurements
Accurate measurements of the dose rate at regions in immediate proximity to the
source are imperative in HDR brachytherapy. Due to the large dose gradients as-
sociated with 192Ir source, a slight change in measurement position leads to a large
variation in measured dose rate. Determination of the position of the source using
a triangulation algorithm requires an accurate knowledge of the relative source-to-
detector distance (SDD) dose response of the MP in a water equivalent phantom. It
is not essential that the measurement results match the expected data set, as it is ex-
pected that the energy dependence of the MP will cause discrepancies. It is, however,
necessary to perform a characterisation so that an estimate of distance can be later
calculated from a measured detector response.
Methods
The response of the MP due to the HDR 192Ir source was measured within a 30×30×30
cm3 SW phantom. The MP was placed above 100 mm of SW, and aligned so that
the middle MP detector element was at the centre of the phantom. The HDR plastic
catheter was aligned inside the phantom using the top slab of the MPh, ensuring that
the catheter crossed over the middle detector of the MP. The SDD was changed from
7 mm to 151 mm by moving the HDR catheter position along the z-axis (Figure 4.6).
The HDR source was then programmed to dwell directly perpendicular to the face of
the sensitive volume of the middle MP detector, for a dwell time of 30 s.
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Figure 4.6: Source-to-detector distance dose experimental set-up.
The MP was then set to measure the generated current, before, during and after the
source dwell. This allowed for a baseline subtraction to be performed on each channel
of this measurement. As there is a low event rate associated with measurements at
large SDDs, to obtain a detector response with low fluctuations, the integration time
was varied from 100 µs to 9920 µs.
The uncertainty associated with the alignment in the x and y plane was estimated to
be as large as ±3.5 mm. It is estimated that the SW thickness used were accurate to
0.05 mm. Based on a the maximum geometrical distance using the ± 3.5 mm and the
accuracy of the SW thickness, a determination of the source-to-detector distance was
calculated to a maximum of 0.8 mm at 7 mm, which decreases as the SDD becomes
larger.
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Figure 4.7: The calculated source-to-detector distance uncertainty.
Results
The relative SDD response of the MP to a 192Ir source is shown in Figure 4.8. Shown
for comparison is expected response for the Nucletron microSelectron R© mHDR-v.2.
afterloader source, based off the Monte Carlo obtained data by Taylor and Rogers [28].
The MP response was normalised to 100% at 16 mm SDD. This distance was chosen
to minimise the effect of positional uncertainty introduced in aligning the MP and the
estimated effect of the energy response of the diode associated with the softening of
the 192Ir spectra with increased SDD. The uncertainty in normalised response is based
on the integral standard deviation of three measurements taken at each depth. Each
uncertainty is then summed in quadrature with the uncertainty at the normalisation
point at 16 mm (2 S.D).
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Figure 4.8: Source-to-detector distance dose experimental results.
Based on the TG-43U1 protocol calculation of the radial dose function was performed
using the MP SDD dose response, taking into the account the radial distance and
the 192Ir source physical dimensions, shown in Figure 4.9. This calculation takes into
account the 1/r2 dependence and allows for deviations from the theoretical to be seen.
The uncertainties (2 S.D) shown in the figure are a combination of the uncertainty in
normalised response (Type A) and the uncertainty in determining the SDD (Type B)
found in Figure 4.7.
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Figure 4.9: Experimentally measured radial dose function.
Due to the lifetime of 192Ir, the HDR source is typically replaced every 3-4 months.
The current generated within the MP is therefore expected to be at a maximum when
the source has recently been replaced, at approximately 48 mGy.m2.h−1, and lowest
when the source is due to be replaced for the same SDD. When measuring at large
SDDs, it is vital that the MP system is capable of obtaining a signal suitable for
performing an accurate measurement.
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Figure 4.10: The expected upper and lower bounds of current generated in the "Magic
Plate".
To derive the expected maximum and minimum generated current with the MP for
each SDD, the MP response values for the SDD were divided by the source activity at
the time of measurement, and multiplied by either the maximum or minimum source
activity to be expected. Figure 4.10 shows the expected current generated for these
two cases for varying depths within Solid Water R©. The lower bounds is expected to
be larger than the maximum baseline current by factor of 25.
4.4 Angular dependence of the "Magic Plate"
The intrinsic asymmetric structure of the epitaxial diode of MP and the energy range
of the gamma photons emitted by the 192Ir may result in directional dependence for
each detector. To predict the angular response of the epitaxial diodes in the MP for
any position of the source, it is necessary to characterise the angular response of the
single diode of the array along both the azimuth and polar angles. The MP detectors
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were mounted onto the Kapton substrate prior to testing, so it is difficult to assess the
angular dependence of each detector without removal. To overcome this, the angular
dependence of two epitaxial diodes from the same manufacturing batch were tested
that were separately mounted onto a Kapton pigtail.
Due to the highly controlled production process, reproducibility of detectors in the
same batch is high. In addition, the CMRP patented technique used to embed the
detector into the MP flexible carrier attempts to reduce the possibility of introducing
any additional angular dependence, and is also used in the assembly process of the
detectors onto the Kapton pigtails.
Methods
To measure the azimuth angular response, the diode was placed in a rotatable cylin-
drical phantom that was encased in a cubic phantom of 30×30×30 cm3 SW, to en-
sure full body scattering conditions. A single HDR catheter was placed at 20 mm
SDD, as seen in Figure 4.11. The initial position, θ = 0◦, was taken as the orien-
tation of the detector’s sensitive volume was "face-up" relative to the source. Using
the Nucletron microSelectron R© mHDR-v.2. afterloader source, the HDR afterloader
was programmed to position the source to the final dwell position at the end of the
catheter, dwell for 45 seconds at this position and then retract. The cylindrical insert
was rotated in a clockwise direction for a total of 180◦ rotation with measurements
taken at every 30◦ increment.
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Figure 4.11: Azimuth and Polar measurement set-up.
Polar angular response characterisation required the design of a specific phantom where
the HDR source would move on an arc of radius 50 mm, centred at the detector to
minimise the effect of any variation in the SDD and the anisotropy effects of the source.
A schematic diagram of the phantom is shown in Figure 4.11. The detector was placed
side on, into a groove that had been machined into the phantom. In this orientation,
when the source was at the final dwell position of the catheter, the detector’s sensitive
volume faced the perpendicular axis of the source at 0◦. By stepping the source in
13 mm increments around the 5 cm arc radius, a step of 15◦ could be obtained. The
source was driven around an arc of 180◦.
Results
The directional dependence of the epitaxial diode response is shown in Figure 4.12.
Both data sets are normalised to 100% at 0◦. The azimuth data was taken using the
cylindrical insert as shown in Figure 4.11. The uncertainty in determining the angle
for this phantom was ± 2.5◦ (Type B). The polar data was taken using the phantom
shown in Figure 4.11. As the source was driven by the HDR loader to set points
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with 1 mm accuracy, the estimated uncertainty is calculated to be 0.6◦. The Type
A uncertainty in response in both sets is ± 1.6% (2 S.D.), and is primarily due to
electronic noise associated with using a single detector on a kapton tail.
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Figure 4.12: The angular response of the epitaxial diode.
Both data sets show a variation in response of the diode of 15% between the top
face (0◦) and bottom face (180◦) of the epitaxial detector, but is uniform in ± 5%
of variation for angles range of 0 ± 60◦and 180 ± 60◦. Data measured in the polar
direction between 0 – 110 ◦ were excluded due to the difficulty in placing the sensitive
volume of the detector directly at the centre of the rotation, resulting in aberrant
values.
4.5 Discussion and conclusion
The MP detector and the AFE DAQ system have shown to exhibit a low baseline
current of an average of 1.62 ± 1.65 pA (2 S.D). Due to the radio-frequency shielding
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of the MP, it is expected that the majority of baseline current be due to the connected
electronics readout system. The majority of the baseline appears on only one of the
AFE chips, and could be due to the connection of that side of the MP to the AFE
board, and the connection and placement of the AFE chip on the board. Influence
due to mains power seems to have the most impact on the baseline current level of
these channels and the AFE DAQ system board and encasing of the electronics could
be refined to minimise this in later development versions. For fluctuations not centred
at 0, it would be possible to perform a baseline subtraction of the centring value for
those MP detectors.
A characterisation of the MP response with varying amount of SW was performed to
determine the suitable amount backscatter needed for measurement. It was found that
while there was an increase in response with material, the change decreased following
an exponential trend. A minimum of 50 mm of SW placed both above and below the
MPh was found to be sufficient, with amounts larger than this equating to a less than
1% increase. For consistency of measurement, all MPh pre-treatment testing in this
work was performed using a 30×30×30 cm3 phantom, with all other measurements
using at least a 50 mm thickness.
By varying the HDR source-to-detector distance through SW, measurements of the
MP response were obtained that can be used to estimate the SDD during the triangu-
lation procedure. It was seen that the MP did not exhibit any over-response and re-
sults matched the TG-43U1 protocol data specified for the Nucletron microSelectron R©
mHDR-v.2. afterloader source. The MP matched the radial dose function data with
an average difference of 2.5%, over the depth of 7 – 150 mm, with an maximum differ-
ence of 12.4%. However, this result is markedly different to that previously presented
by Espinoza et al. [16], where a large over-response was seen for SDD over 15 mm,
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with a 40% difference at 70 mm. It is suggested that this over-response could have
been due to the sensitivity of this silicon detector to the larger lower energy scatter
contribution. This previous study was performed using a MP sample that had been
pre-irradiated to 20 kGy equivalent dose in water.
All of the results presented in this work, except for the angular dependence measure-
ments found within this chapter, were performed with a different sample of MP, which
has had an estimated pre-irradiation of greater than 40 kGy equivalent dose in water.
This second MP also had a 40 µm layer of aluminium surrounding the complete kap-
ton substrate to shield the detector from radio-frequency noise. This possibly filtering
of the low energy through the aluminium shielding, could explain the lack of over-
response, as relatively higher energy contributions could be deposited. However, this
would have to be confirmed through an in-depth investigation, involving experiments
and Monte Carlo simulations.
The angular dependence measured found a variation of 15% in the response between
the top and bottom face of the epitaxial detector and less than a 5% variation for
both faces for ± 60◦. It is suggested that the angular dependence is due to the
asymmetry involved in a silicon detector when the depletion layer is close to the
front surface [91, 92]. As there is an asymmetrical boundary region surrounding the
sensitive volume, where charge collection is not ideal, this results in a lower amount of
charge collected per detected event in this part of the detector. The structure of the
detector, in conjunction with the energy dependence of the response of silicon for the
192Ir source and attenuation of secondary particles through the passive silicon, is most
likely the cause of the observed variation of the response. This could be investigated
further using Monte Carlo simulations by reproducing the detector design and sensitive
volume, and rotating it in respect to a HDR source. The obtained angular response
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will be used to provide a small correction factor for the source position calculation,
when the source is not directly above or below the detector.
Chapter 5
The determination of dwell
positions and times using the
"Magic Plate"
The previous chapter assessed the feasibility of the MP for use in high dose rate
brachytherapy. The system was shown to have a low baseline current, a large dynamic
range of measurement that allows for both close and far away radiation detection, and
a minimal angular dependence around the top and bottom face of each detector.
This chapter describes the method of source position localisation using multiple detec-
tor elements, that has been implemented into the analysis software2. A description of
the method for the calculation of the source dwell positions and times for a measured
2 Part of this chapter has been published in Medical Physics:
A. Espinoza, B. Beeksma, M. Petasecca, I. Fuduli, C. Porumb, D. Cutajar, S. Corde, M. Jackson,
M. L. F. Lerch, and A. B. Rosenfeld, "The feasibility study and characterization of a two-dimensional
diode array in "magic phantom" for high dose rate brachytherapy quality assurance.," Medical Physics,
vol. 40, p. 111702, Nov. 2013.
A. Espinoza, M. Petasecca, I. Fuduli, A. Howie, J. Bucci, S. Corde, M. Jackson, M. L. F. Lerch,
and A. B. Rosenfeld, "The evaluation of a 2D diode array in "magic phantom" for use in high dose
rate brachytherapy pretreatment quality assurance," Medical Physics, vol. 42, no. 2, pp. 663-673,
2015
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treatment is also presented.
5.1 Source localisation using multiple detectors
A method for determining the position of the HDR source was devised and patented by
A. Rozenfeld and M. Zaider [93,94]. Localisation is based upon an iterative procedure
where the source position is estimated, and then repeatedly refined based upon the
agreement of the predicted geometric distance from the source to the detectors against
those measured by the MP detectors. This method is implemented into BrachyPix and
is used to calculate the source position with a minimal amount of processing.
The MP is a 2D array of diodes where each detector element is measuring the energy
deposited by the gamma photons or secondary electrons emitted by a source with
no directional information. However, the radial distance, r, can be estimated by
taking into account the diode response, normalised to the activity of the source, as
a function of distance and angle. The correlation of the responses of three or more
detectors can be used to identify the position of the source in three dimensions using
a triangulation method based on estimation and iteration. As three non-collinear
detectors are the minimum for localisation of the source, selection of more than three
allows for redundancy in estimation of the x, y and z coordinates of the source, and
inaccuracy reduction.
Every MP detector can be used for estimating the source position, however only the
detector with the highest response and it’s immediate neighbours (typically a 3×3
subset) were considered, when used in phantom. This was done to minimise the
uncertainty in the calculation due to the lower signal from the detectors at larger
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distances from the source, as well as minimise uncertainty due to the non-isotropic
response of the detector and source itself. However, a larger number of detectors are
selected for use in in-vivo measurements, as the MP response is more uniform at larger
SDDs due to the flattening of the dose profile. This technique requires the accurate
characterisation of the detector response to 192Ir gamma spectrum in terms of relative
SDD dose and angular responses, as was performed in Chapter 4.
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Figure 5.1: The "Magic Plate" coordinate system.
The origin of the coordinate system is set at the bottom left of the MP (Figure 5.1)
and is used to provide the coordinates of each detector di on the "Magic Plate". The
HDR source is located at position S(a, b, c), relative to the coordinate system.
The data acquisition system integrates the current generated in each MP detector
during a set integration time. The software tool searches the data set for the detector
with the highest response, shown as detector Dmax in the coordinate system. The de-
tector’s index, i, within the array is determined and the responses of the 8 surrounding
detectors are retained. When the detector with the highest response is found to be on
the edges of MP, a larger number of surrounding detectors are included.
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The response of the i-th detector, Ri, is a function of its distance, ri, from the HDR
source. A fitting function based upon the SDD dose response measured in Chapter 4
for angle θ = 0◦, is
Ri = f(ri)× SK ×
R0
SK0
(5.1)
where SK is the source strength at the time of measurement, and R0 is the average
current of the MP at SDD 15 mm, at source strength SK0. The distance between the
source and the detector i, can then be calculated by the inverse function
ri = f−1
(
Ri × SK0
SK ×R0
)
(5.2)
The calculation of SDD using the inverse function results in an average absolute dif-
ference of 0.82 ± 1.10 mm (2 S.D) across the range of SDDs in Figure 4.8. The
uncertainty in determining the calculated SDD based on the fitting procedure was on
average 1.15 ± 0.73% This estimation of the distance from the source to the detector
is calculated based upon the assumption that the detectors do not display an angular
dependence. However, once a rough source estimation is performed, the angular cor-
rection factors is applied and the algorithm is repeated. Based on the several derived
distances, ri, the source position Ses(a, b, c), in the MP frame is estimated. The geo-
metrical distance, di, between Ses and the coordinate of the i-th detector Di(xi, yi, zi),
is calculated by
di(a, b, c) =
√
(a− xi)2 + (b− yi)2 + (c− zi)2 (5.3)
To determine the true source position, the geometrical distance, di, is fitted to the
derived distance, ri, by adjusting the estimated source position. Employing a non-
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linear least squares fit method to determine the estimated source position, the best
fit requires that an estimate of error assessment be at a minimum value [95]. In least
squares fitting, the estimate of error assessment can be expressed as the sum of squares
of the relative error, χ2
χ2(a, b, c) =
n∑
i=1
(
di(an, bn, cn;xi, yi, zi)− ri
ri
)2
(5.4)
and assumes that the derived distance, ri, is correct. As there is an uncertainty
associated with determining ri, if the estimated source position were equal to the true
source position, then calculating the square of the sums of the percentage difference
of the values of di and ri (Equation 5.4) would result in a minimum value.
A theoretical calculation of χ2 was performed by estimating the dose rate for each MP
diode for a source coordinate of S(40mm, 50mm, 10mm) using the TG-43U1 protocol.
The dose rate was then converted into radial distance by the inverse function, and a
3D χ2 map was calculated. The map was calculated by varying the estimated source
position, Ses from 0-100 mm in all 3 dimensions, with a step of 0.2 mm, and calculating
χ2. The 2D χ2 map for the estimated source position at z = 10 mm is shown in Figure
5.2
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Figure 5.2: χ2 for z = 10 mm.
It can be seen that for the z = 10 mm plane, there is only one global minimum, at
P (40, 50). It is to be noted that the scale is in powers of 2, meaning that the is a very
large gradient towards this minimum. By taking a line profile along each of the source
coordinates (Figure 5.3), it is possible to see that the minimum value of χ2 for each
coordinate matches that the modelled source coordinate.
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Figure 5.3: χ2 2D profile.
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Minimising the estimate of error
Determining a source position that gives the minimal value to the estimate of error
assessment, χ2, can be performed in multiple ways. One method is to compute by
a brute force approach, where each source coordinate is adjusted individually until a
minimum value is determined, similar to that used to generate Figure 5.2. For this
work, a multi-variable Newton’s method approach has been adopted to determine the
source position in three dimensions.
Newton’s method is used to determine the roots of a function by finding successively
better approximations. In this analysis, it is necessary to determine the minimum
values of χ2 for all three dimensions of the estimated source position, and can be
expressed as
∂χ2(a, b, c)
∂a
= ∂χ
2(a, b, c)
∂b
= ∂χ
2(a, b, c)
∂c
= 0 (5.5)
Newton’s method for the three source coordinates can be expressed for the k-th iter-
ation as
ak = ak−1 − δak−1
bk = bk−1 − δbk−1 (5.6)
ck = ck−1 − δck−1
where δa, δb and δc are the changes made to the source position to produce the
improved approximation. These changes can be determined by solving a set of linear
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equations, expressed in matrix form as

∂2χ2
∂a2
∂2χ2
∂a∂b
∂2χ2
∂a∂c
∂2χ2
∂b∂a
∂2χ2
∂b2
∂2χ2
∂b∂c
∂2χ2
∂c∂a
∂2χ2
∂c∂b
∂2χ2
∂c2


δa
δb
δc

=

∂χ
∂a
∂χ
∂b
∂χ
∂c

(5.7)
This process is repeated until all δ’s are sufficiently small, or until further estimations
of the source coordinates fail to reduce χ2. This approach can converge rapidly to a
minimum when close, as all three source coordinates are modified in a single iteration,
but requires a suitable initial guess to increase the likelihood of convergence.
The initial guess is determined by the coordinates of the detector with the highest
response, Dmax(xmax, ymax, z = 0), as the source is assumed to be closest to this
position. The sum of the squares is calculated using the first estimation of the source
position,
S0es(a0, b0, c0) = Ses(xmax, ymax, rmax) (5.8)
Once an estimation of the source position is found, a correction factor is applied to the
response of each of the MP detectors to take into account the angular dependence of the
detectors found in Chapter 4. The source position is then re-estimated using the above
method, but uses the initial estimated source position of the previous calculation.
5.2 Dwell position and time calculation
A method for determining the HDR 192Ir source position using the two dimensional
detector array MP has been introduced. For every measurement frame where the
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detectors’ response is above a threshold value, a calculation of the source position is
performed. For pretreatment verification using MPh, two rows of 10 catheters are
inserted into trenches 6 mm above and below the MP array. The catheter’s are spaced
at 10 mm, with the above row placed between the columns of the MP detector array,
and the below row directly aligned with the detector columns. Using the coordinate
system previously described, the catheters are at z = ±6 mm, and at an x-coordinate
along the detector rows, with the catheter length along the y-coordinate.
Using the result of the source tracking algorithm, the x-y-z measurement of the source
is translated to catheter number and position in the catheter, at each frame of mea-
surement. As the MP DAQ acquires the response of the detectors at a set frequency
it is possible to see how the position of the source varies with time.
Figure 5.4 shows the theoretical motion of the HDR source moving along the y-
coordinate with a 10 mm step size, and 2 second dwell time. The source starts from
outside the catheter, is driven to the position 100 mm in the catheter and then moves
towards the tip of the catheter. This theoretical calculation neglects the transit motion
of the source from dwell position to dwell position and assumes no fluctuations in the
determination of the source position at each point.
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Figure 5.4: Theoretical source tracking - 10 mm step size, 2 second dwell.
From this source tracking calculation, it is possible to generate a position-frequency
histogram, Figure 5.5, where each count corresponds to a single calculation of the
source at that position. The bin width is set to 0.1 mm and accepts positions from -5
to 105 mm. When the source is at the same position for multiple measurements, i.e.
when the source is dwelling, multiple counts at that position form a peak.
5.2. Dwell position and time calculation 97
0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
Co
un
ts
P o s i t i o n  ( m m )
 F r e q u e n c y  =  1  k H z
Figure 5.5: Theoretical dwell position-time histogram – 10 mm step size, 2 second
dwell.
The number of counts under each peak of the histogram corresponds to the measured
dwell time, as the time for each count is dependent on the sampling frequency, Fmeas,
of the system. Each count in bin i is converted to time ti by
ti =
counti
Fmeas
(5.9)
The start and end positions, xs and xe respectively, of each peak are determined based
upon a threshold of 0.02 s. The dwell time is then calculated by summing up the time
in the histogram bin from the peak start and end
tdwell =
xe∑
i=xs
ti (5.10)
The dwell position is calculated by the determining the centre of the peak by
xdwell =
xe∑
i=xs
xiti
tdwell
(5.11)
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and uncertainty is determined by the centre of the peak and the standard deviation,
σdwell
σdwell =
√√√√√√
xe∑
i=xs
x2i ti
tdwell
− x2dwell (5.12)
The error in dwell position is taken by 2 times the standard deviation.
This results in the set of dwell positions and times for that particular catheter number.
The set of dwell positions and times are shown in Figure 5.6.
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Figure 5.6: Theoretical dwell position and time – 10 mm step size, 2 second dwell.
As this is a theoretical calculation with no variation in the source position determina-
tion, there has been no uncertainty in the dwell position. This would not be the case
in real measurements.
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5.3 Discussion and conclusion
In this chapter, a description of the source tracking algorithm and dwell position and
time determination has been presented. The source tracking algorithm shows that by
taking the response of three or more detectors, it is feasible to calculate the solution
of the source position by using an iterative method for a single measurement frame.
By aggregating multiple frames, the dwell positions and times can be determined by
the dwell position-time histogram.
This method of source tracking relies an accurate determination of the SDD from the
detectors response. The fitting equation used was found to have an average absolute
difference of 0.82 ± 1.10 mm (2 S.D) over the range of 7 – 150 mm, representing a
less than 2 mm difference in the SDD. As multiple detectors are used in the source
position determination procedure, this should minimise the effect of this difference.
The method also assumes that the set of MP detectors are very similar, in terms of
geometry, region of charge collection, energy response and angular dependence. This
assumption is reasonable due to the well developed fabrication method of the silicon
detectors.
There are limitations to this method when individual MP detector responses have
a very low signal-to-noise ratio, resulting in a high variation in response. This is
compensated for in the method by only considering detector responses with a large
enough signal, excluding the detectors with low responses. However, when the HDR
source is above or close to the MP field of view (FOV), there are fewer detectors with
higher responses, potentially resulting in an incorrect determination of the source
coordinate. This FOV effect is investigated in further detail the next chapter.
5.3. Discussion and conclusion 100
The MPh has been designed to have each catheter x and y coordinate fixed; the
movement of the source is only along the y-coordinate. This simplifies the use of the
dwell position-time histogram method to only account for the y-coordinate, instead of
in three-dimensions. The methods presented in this chapter have been implemented
into BrachyPix software for post-processing analysis, and are verified experimentally
in the following chapter.
Chapter 6
Experimental verification of source
tracking and dwell position
determination
The previous chapter outlined the mathematical description of the MPh source local-
isation method, and methods for determining dwell positions and times. The work
presented in this chapter details the experimental verification of these methods3. A
single catheter plan was measured by the MPh with all dwell positions and times de-
termined. The calculated dwell positions were then compared to exposed EBT3 film,
placed above the MP detector during delivery. The minimum resolvable interdwell
distance and dwell time were also assessed.
All plans were delivered using the Nucletron Flexitron R© HDR afterloader (Nucletron,
an Elekta company, Elekta AB, Stockholm, Sweden) at the St George Cancer Care
3 Parts of this chapter have been published in Medical Physics:
A. Espinoza, M. Petasecca, I. Fuduli, A. Howie, J. Bucci, S. Corde, M. Jackson, M. L. F. Lerch,
and A. B. Rosenfeld, "The evaluation of a 2D diode array in "magic phantom" for use in high dose
rate brachytherapy pretreatment quality assurance," Medical Physics, vol. 42, no. 2, pp. 663-673,
2015
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Centre, Sydney.
6.1 Source tracking and dwell position and time
determination
The source tracking method determines the source position within 3D for each mea-
surement frame. A basic plan was created to move the source inside a single catheter,
which was then tracked by the MPh detector. The treatment plan was then loaded
into the software for a direct comparison of the determined motion.
Methods
Validation of the source tracking method was performed by programming the after-
loader to drive the HDR source, at 5 mm step sizes and with a dwell time of 2 seconds,
towards the end of the catheter. The catheter was placed inside the MPh and posi-
tioned directly above the middle column of the MP detectors (x = 50 mm) with the
source stepping across the y-coordinate. The MP was at a SDD of 6 mm below the
catheter’s plane. The source position was determined for each measurement frame, us-
ing the developed methods, and were compared to the treatment plan. This was then
repeated for all 20 catheter positions inside of the MPh to determine any potential
problems with the tracking procedure.
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Figure 6.1: Tracking the HDR source inside a single catheter.
Good agreement was found between the positions and dwell times determined by the
HDR source tracking algorithm, and those programmed by Nucletron ONCENTRA R©
TPS, as seen in Figure 6.1. It was found that the source travels from the afterloader,
and dwells at the furthest dwell position away from the catheter tip, and then moved
progressively closer. It was possible to determine the motion of the source as it moves
from dwell position to dwell position, as a timing resolution of 1 ms was used. The
transit motion is seen in Figure 6.2, where both graph scales have been adjusted to
show 4 dwell positions. As stated in Chapter 2, the TPS neglects the time needed to
move the source from dwell position to dwell position.
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Figure 6.2: Zoom of the tracking of the HDR source.
A position frequency histogram was generated from the source tracking calculations
for the single catheter. Each histogram had a bin width of 0.1 mm; the counts of
source positions is related to the electronic sampling frequency, with each count equal
to 1 ms time at that position. Figure 6.3 shows the histogram for the 5 mm step size
plan. Each dwell point was found to be a narrow peak, where the centre position of
each peak was equal to the dwell position. The number of counts, converted to time,
under each peak is equal to the total dwell time for that dwell position.
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Figure 6.3: Measured dwell position-time histogram for the single catheter plan.
It was found that only the dwell position at 90 mm was calculated to have the correct
dwell time, stated by the TPS plan. Each dwell position was planned to have the same
dwell time and a constant decrease was observed on the remaining dwell positions. The
difference between the planned and calculated dwell times was found to be be 56.45 ±
13 ms (2 S.D.), and is most likely due to the Nucletron Flexitron R© HDR afterloader
compensating for the source transit time. It is expected that the this difference would
be larger than 10 ms, which is derived assuming that the source moves at the maximum
speed of 50 cm/s. Based upon this measured difference, the average source speed across
5 mm for this afterloader is estimated to be 8.86 ± 1.02 cm/s (2 S.D).
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Figure 6.4: Expanded view of the tracking of the HDR source.
By inspecting a single dwell position on the histogram (Figure 6.4), the uncertainty
of the calculated dwell position can be seen to cover the peak. The TPS position
was found to be within the error of the calculated dwell position, determined from
Equation 5.12.
By analysing the results from all 20 catheters, it was found that there existed a dif-
ference between the measured dwell position and planned dwell positions, when the
source was dwelling close to the edge of the MP FOV. Figure 6.5 a) shows the dif-
ference between the measured and planned positions, and b) shows a close up view
around the edge of the MP FOV.
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(b) Measured dwell positions over 0 – 20 mm.
Figure 6.5: Difference between the measured dwell position and planned.
It is clear that when the source is dwelling at positions between 0 - 10 mm the difference
becomes larger than ± 1 mm, and up to 3.5 ± 0.5 mm. The average difference across
the entire range was found to be 0.08 ± 1.12 mm (2 S.D), but when considering only
the range of 10 – 90 mm, the average difference was reduced to 0 ± 0.84 mm (2 S.D)
with a lower variation.
6.2 EBT3 film comparison
The position of the source is related to the tip of each catheter, which is registered in
the frame of the MPh with coordinate system origin based on a left corner detector.
A position calibration test, relative to the MPh origin, was performed by driving the
source to multiple positions in a single catheter, and simultaneously measuring with
the MP in the MPh and exposing EBT3.
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Methods
Two pieces of EBT3 film were registered to the MPh, by fixing them rigidly between
the MP and the top catheter plane. The MPh was CT scanned with a single piece of
EBT3 film and the MP detector inside the MPh. The catheters were inserted in the
MPh prior to the scan, with metal markers placed inside each catheter tip. The CT
scan was used to confirm the alignment of the EBT3 film against the MP and to plan
the delivery of 6 dwell points separated by 20 mm within the catheter.
The plan was delivered using the Nucletron Flexitron R© HDR afterloader. The irradi-
ation of a second piece of film by the HDR source resulted in a circular distribution of
the change in colour of the film at each dwell point. The centre of mass of each source
image on the film and the dwell positions calculated by the software were compared
with the planned dwell positions.
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Figure 6.6: The difference between the calculated and planned dwell positions for the
MPh calculation and EBT3 film for single catheter measurement.
Figure 6.6 shows the difference along the catheter length between the calculated and
planned dwell positions for the position calibration test. The source was driven through
a single catheter towards the tip, and the EBT3 film was irradiated while the MPh
acquired. Six dwell positions were identified by both the software and from the film
analysis, and all differences were less than 0.8 mm. An uncertainty of ± 0.25 mm
(Type B) was estimated due to the coordinate registration of the film to the MPh
reference frame.
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6.3 Determination of the minimum measurable
interdwell distance and dwell time
The Nucletron Flexitron R© HDR afterloader can be programmed to drive the HDR
source to dwell positions with varying interdwell distances (the distance between two
dwell positions) and dwell times, with a minimum of 1 mm and 0.1 s, respectively.
To be feasible for plan verification, the MPh system must be able to determine dwell
positions and times accurately, over this range of step sizes and dwell times.
Methods
To assess the dwell position resolution of the system, the afterloader was programmed
to move the HDR source through a single catheter, with progressively reduced step
sizes down to 1 mm. Each dwell position had a programmed dwell time of 3 s and
was measured using the MPh system. The transit time of the source from one dwell
position to the next was also calculated.
To assess the dwell time resolution of the system, the HDR afterloader was pro-
grammed to drive the source to 3 dwell positions within a single catheter for the
same amount of time. The measurement was repeated for a range of dwell times from
10 s down to 0.1 s.
Results
As seen in Table 6.1, the dwell positions were determined by the MP, and the system
was capable of resolving the dwell positions separated by 1 mm. The last two dwell
positions were close to the catheter tip and the edge of the FOV of the MP, and used
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fewer detectors to calculate the source position. As the tracking algorithm is based
upon the agreement of the detector with the largest response and its neighbours,
reduced numbers of detectors can result in a shift in true position.
Each prescribed dwell time, apart from the first dwell position calculated, was found to
be reduced from the planned 3 s. This reduction in dwell time agreed with the calcu-
lated time taken to move the source to that position and was found to be proportional
to the interdwell distance.
Planned Position
(mm)
Measured
position (mm)
Measured dwell
time (s) (± 0.001 s)
Measured transit
time (s) (± 0.001 s)
83.6 83.49 ± 0.14 3.015 -
53.6 53.82 ± 0.12 2.792 0.219
33.6 34.23 ± 0.14 2.849 0.172
23.6 23.95 ± 0.18 2.919 0.109
18.6 18.27 ± 0.16 2.946 0.066
14.6 15.06 ± 0.16 2.987 0.040
11.6 11.54 ± 0.16 2.976 0.054
9.6 8.72 ± 0.18 2.989 0.041
8.6 7.35 ± 0.16 2.991 0.027
Table 6.1: The comparison of the planned position in an HDR catheter and the position
and time calculated using the MPh.
The minimum measurable dwell time for the MPh system was evaluated by using
three dwell positions, at 13.6 mm, 18.6 mm and 28.6 mm from the catheter tip, and
varying the planned times. Again, each position was set to have the same dwell time,
but varied when calculated, except for Position 1, which was the first the source was
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driven to.
In Table 6.2 it can be observed that the minimum dwell time that was calculated was
0.067 ± 0.001 s. For planned dwell times of 0.1 s, Position 2 was expected to have a
time of 0.01 - 0.02 s, but could not be detected in the position frequency histogram.
Planned dwell
time (s)
Measured dwell time (s) (±0.001 s)
TPS Position 1 Position 2 Position 3
(28.6 mm) (18.6 mm) (13.6 mm)
10 10.012 9.914 9.955
5 5.015 4.908 4.951
3 3.014 2.898 2.955
2 2.014 1.911 1.951
1 1.013 0.916 0.957
0.5 0.512 0.414 0.458
0.3 0.315 0.213 0.256
0.2 0.212 0.109 0.155
0.1 0.107 Unable to determine 0.067
Table 6.2: Determination of the minimum measurable dwell time.
6.4 Discussion and conclusion
The combination of the source tracking algorithm and the high timing resolution of
the AFE DAQ system, made it possible to determine the source position at 1 ms
intervals. This allowed for the accurate measurement of the source motion while in
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transit and for dwell time determinations to overcome the programmable limitations
of the afterloader system.
The MPh system has shown that it can be used to resolve dwell positions spaced apart
by 1 mm or larger, but the verification of the accuracy of all dwell times set by the
TPS is impossible, as the afterloader itself was found to always modify the actual
dwelling time. A relationship exists between the absolute dwell time reduction and
the interdwell distance, which is noticeable for all dwell times. This relationship will
be explored in further detail in the subsequent chapter. It has, however, been demon-
strated that dwell positions programmed to 0.1 s were able to be distinguished, when
there was no effect of the afterloader compensating for the transit time. With further
development of BrachyPix and integration with the TPS, it would be possible to eval-
uate the clinical significance of the modified dwell times on the patients plan, allowing
for modifications to the treatment plan to achieve clinical goals when necessary.
It was observed that there was a shift in dwell positions determination when the source
was close to the edges of the MPh FOV. This shift was found to be as a large as 3.5 ±
0.5 mm when the source was at 0 mm, with the effect being minimised as the source
was between 10 – 90 mm. When ignoring the dwell position differences between 0
– 10 mm, the average difference was between ± 0.84 mm. This effect is most likely
due to the MP detectors not surrounding the HDR source, causing the algorithm to
incorrectly determine the source position.
For accurate source dwell position calculations, the TPS plan should be configured to
set the last dwell points at least 5 – 10 mm away from the edge of the MPh FOV.
While there is a reduction in usable catheter length for this particular design of the
MPh, it will be possible to measure the dwell position accurately within a total range
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of 80 – 90 mm.
Chapter 7
The source motion and transit dose
components
Previous evaluations of the average transit speed using direct measurements have
varied between 5.4 to 35 cm/s for a range of step sizes, for a wide range of measurement
techniques [64–68]. The average source speed using the single element of the MP
detector and the X-Tream electronics system have previously been reported by the
author [16]. By sampling the diode response with high temporal resolution of 1 MHz,
an estimation of the transit times and average speeds were made.
This chapter presents a more robust method for determining the instantaneous source
speed, as opposed to the average, based upon the timing resolution of the AFE DAQ
system and the source tracking method. The HDR source motion was evaluated as the
source entered the catheter, stepped between dwell positions, and then returned back
to the afterloader. The transit dose components were determined for the MP plane
by integrating the dose rates calculated using the TG-43U1 protocol, based upon the
discrete source position.
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Measurements were performed using the Nucletron microSelectron R© mHDR-v.2. after-
loader (Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden) at the Prince
of Wales Hospital, Sydney.
7.1 The HDR source in motion
Dwell times and speed profiles were measured for a Nucletron microSelectron R© mHDR-
v.2. afterloader using the MP. Due to the fast acquisition sampling frequency of the
AFE DAQ system, of up to 10 kHz, it was possible to measure the response of the
MP detector while the source was in transit. The measured responses were then used
to determine the source position with high temporal resolution.
Methods
A single catheter delivery was programmed in the afterloader console, featuring two
dwell positions with varied interdwell distances. The HDR source was set to step to
the first dwell position in the catheter, and remain for 2 seconds. The source was then
set to move to the subsequent position, where it remains for an additional 2 seconds,
before returning to the afterloader. The step size was varied from 2.5 to 100 mm
and a sampling frequency of 4 kHz was used, giving a timing resolution of 250 µs per
measurement.
Results
The source tracking for the 50 mm step size is seen in Figure 7.1 a). By inspecting the
tracking data during the transit component of the motion, in Figure 7.1 b), a distinct
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non-constant motion of the source can be observed.
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(b) Transit component.
Figure 7.1: The source tracking for a 50 mm step size.
By taking the derivative of the source motion along the y-coordinate, with respect to
time, it was possible to obtain the instantaneous speed of the HDR source. Figure 7.2
shows this instantaneous speed for the 50 mm step size. This calculation shows that
the HDR source increased in speed, and approached the 50 cm/s stated maximum,
but then slowed down to ∼25 cm/s. The speed was found to oscillate between the 25
– 50 cm/s range.
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Figure 7.2: The 50 mm step size instantaneous speed.
By overlaying the instantaneous speeds for multiple step sizes, the frequency of the
oscillation is seen to be constant. The frequency was determined to be approximately
63.11±9.06 Hz (2 S.D).
1 . 9 5 2 . 0 0 2 . 0 5 2 . 1 0 2 . 1 5 2 . 2 0 2 . 2 5 2 . 3 0 2 . 3 5 2 . 4 0
- 5
0
5
1 0
1 5
2 0
2 5
3 0
3 5
4 0
4 5
5 0
 
 
Ins
tan
tan
eo
us
 sp
ee
d (
cm
/s)
T i m e  ( s )
S t e p  s i z e :
 5  m m
 1 0  m m
 5 0  m m
 7 0  m m
 1 0 0  m m
Figure 7.3: The instantaneous speeds for multiple step sizes.
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The calculation of the average speed for the measured dwell points are shown in Fig-
ure 7.4, alongside published values. Average speeds found within the literature have a
large variation, showing the challenging nature of this characterisation. Measurements
previously published by the author, Espinoza et al. [16], were performed using a single
element of the MP, the Epitaxial diode, and were connected to a single channel data ac-
quisition system with 1 µs sampling frequency, named the X-Tream electronics system.
Both experiments were to assess the average speed of the Nucletron microSelectron R©
mHDR-v.2. afterloader, with the MPh measurements occurring approximately two
years after the X-Tream.
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Figure 7.4: The average speed for multiple step sizes compared to the literature.
The X-Tream system sampled the charge generated within the diode at 1 MHz fre-
quency, but these results could only be used to obtain the average speed of the source
based on the changes in charge over time. The calculation of the average speed taken
from the MPh are in good agreement with those previously taken with X-Tream. Al-
though the discrepancy of absolute value is related to the specific afterloader, this
direct measurement technique shows a similar trend of the source velocity with the
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step size.
7.2 Transit dose calculations
BrachyPix has an built-in dose calculator based upon the TG-43U1 protocol. By using
the measured source position sampled at 4 kHz, the transit dose at certain points could
be calculated. Assuming the source motion is discrete at this timing resolution, the
dose delivered was the calculated dose rate multiplied by the timing resolution. The
50 mm source tracking calculation was used to generate integral dose maps to compare
the effect of the transit dose along the MP plane.
Methods
Two-dimensional 10×10 cm2 dose maps along the MP plane were generated by calcu-
lating the dose to points at 0.5 mm intervals. A source activity of 32 mGy.m2.h−1 was
used in the dose rate calculations. Individual integral dose maps were created for the
components of the HDR source motion. These include the total dwelling dose based
upon the two dwell positions, the entrance and exit dose, and that delivered as the
source steps from one dwell position to the next.
Results
Figures 7.5 a-e) show the calculated integral dose maps. The transit motion of the
source delivered a maximum of 0.9 cGy for the source activity of 32 mGy.m2.h−1 to
the MP plane.
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(a) Total dose with central line.
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(b) Dwell dose only.
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(c) Entrance dose.
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(d) Stepping dose.
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(e) Exit dose.
Figure 7.5: Calculated integral dose maps using BrachyPix.
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A line profile was taken along the centre vertical axis of all the calculated dose maps.
Figure 7.6 shows the total dose and the individual contributions for the 50 mm step
size. It is possible to see that overall, each movement of the source delivers a relatively
low amount of dose, when compared to the total dwelling dose.
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Figure 7.6: The dose profile calculated on the MP detector plane.
The percentage of transit dose to the total dose was determined for the line profile
and graphed in Figure 7.7. As to be expected, there is a large contribution of transit
dose at positions not in the immediate region of the dwell position, as the dwell dose
only would be low for these points. A greater than 50% contribution of transit dose
can be seen at the position where the source was entering and leaving the catheter.
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Dweling dose
Transit dose
Figure 7.7: The percentage of the dwell dose relative to the total dose.
7.3 Discussion and conclusion
The MP response was sampled at high frequency and was used to determine the motion
of the HDR source as it moved from dwell position to next. The tracking information
derived has shown that the instantaneous velocity of the source is not 50 cm/s as
stated by Nucletron, but increases and decreases over time.
This result was also obtained by Fonseca et al. [67] by using a high speed video
camera to track the HDR source motion. On discussion with Nucletron, it has been
hypothesised that the tension within the source cable causes it to act like a spring as
it moves, while there is also an effect of the friction and slipping of the source along
the transfer tube and catheter inner wall, that contribute to this oscillation in source
speed.
The position of the source in transit was determined with a high timing resolution and
7.3. Discussion and conclusion 124
used to determine the transit dose contribution, as opposed to assuming a constant
acceleration or source speed like methods found in the literature. Using the TG-43U1
protocol to determine the dose at a particular point is computationally faster than
Monte Carlo simulations, but is less accurate due to its assumptions. For this study,
dose was only calculated along the MP plane, but it could be possible to estimate the
total dose to be received by critical organs by taking into account the patient anatomy
and calculating the transit dose based off the measured source motion.
Chapter 8
Pretreatment plan verification
The preceding chapters described and evaluated a method to determine the HDR
brachytherapy source position and calculate the dwell position and timing pattern.
The focus of this chapter is the assessment of the execution of treatment plans by the
HDR afterloader. Two treatment plans, Plan – 1 and Plan – 2, were generated for
this verification test and were delivered to the MPh4. Plan – 1 was created to be a
non-specific treatment scenario and was developed so that the afterloader would drive
the source through each of 20 catheters connected to the MPh, and to dwell at various
positions and times.
This plan was then modified by a Medical Physicist, producing Plan – 2, to simulate
possible errors in delivery by the remote afterloader. These modifications were not
disclosed to the author until after the analysis had been performed to judge the per-
formance of the error detection using a new metric named the position-time gamma
index.
4 The majority of this chapter has been published in Medical Physics:
A. Espinoza, M. Petasecca, I. Fuduli, A. Howie, J. Bucci, S. Corde, M. Jackson, M. L. F. Lerch,
and A. B. Rosenfeld, "The evaluation of a 2D diode array in "magic phantom" for use in high dose
rate brachytherapy pretreatment quality assurance," Medical Physics, vol. 42, no. 2, pp. 663-673,
2015
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All plans were delivered using the Nucletron Flexitron R© HDR afterloader (Nucletron,
an Elekta company, Elekta AB, Stockholm, Sweden) at the St George Cancer Care
Centre, Sydney.
8.1 The position-time gamma index
To quantitatively compare the source position and dwell times in the catheter to the
treatment plan, a new metric was introduced based upon the dose-position gamma in-
dex. The use of the 2D gamma index in quality assurance was first described by Low et
al. [96] and was used to quantitatively compare 2D intensity modulated dose distribu-
tions for external beam radiation therapy. It compares the measured and calculated
distributions by evaluating, point-by-point, the dose difference and the distance to
agreement, the former being sensitive to the homogeneous part of the irradiated area
and the latter to high dose gradients. A pass-fail result, illustrated by a gamma value
lower or higher than 1 respectively, is found depending on an acceptable pre-defined
criteria, typically 3% dose difference and 3 mm distance to agreement.
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Figure 8.1: Geometric representation of the position-time criteria.
Adopting the formalization of this method and applying it to HDR brachytherapy, it is
possible to compare the measured treatment to the plan by evaluating the calculated
source dwell and timing patterns. By using an acceptable distance-to-agreement and
time-to-agreement criteria values, a pass-fail grade (pass if gamma value is equal to
or less than 1) is determined for all calculated dwell positions and times. A graphical
representation of the position-time criteria is seen in Figure 8.1.
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Symbol Equation Description
An(xiA, tiA) N/A The i-th dwell position, xiA, and
dwell time, tiA, of set A in catheter
n.
Bn(xjB, tjB) N/A The j-th dwell position, xjB, and
dwell time, tjB, of set B in
catheter n.
∆x N/A Distance-to-agreement criterion
(DTA).
∆t N/A Time-to-agreement criterion
(TTA).
δnij(xiA, xjB) δnij(xiA, xjB) = |xiA − xjB| δnij is the spatial difference be-
tween the i-th dwell position of set
A and the j-th dwell position of
set B for catheter n.
τnij(tiA, tjB) τnij(tiA, tjB) = |tiA − tjB| τnij is the difference between the i-
th dwell time of set A and the j-th
dwell time of set B for catheter n
Γnij(δnij, τnij) Γnij(δnij, τnij) =√(
δnij(xiA,xjB)
∆x
)2
+
(
τnij(tiA,tjB)
∆t
)2 Generalized Γ index computed for
all dwell positions and times of set
A and set B for catheter n.
γn(xiA) γn(xiA) =
min{Γnij(δnij, τnij)}∀{Bn(xjB, tjB)}
The γ index - the minimum gener-
alized Γ for the set B, Bn(xjB, tjB)
dwell positions and dwell times in
catheter n.
Table 8.1: Definitions of the HDR position-time gamma index.
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The formalization of this method is found in Table 8.1. Two sets, A and B, represent
the calculated and TPS dwell position timing pattern in catheter n. The gamma index
compares all the dwell positions in set B against those in set A. The gamma index
was calculated twice to first compare the treatment calculated (set B) by the MPh
against the treatment plan (set A), and then for the treatment plan (set B) against the
calculated (set A). This increases the robustness of the method, taking into account
cases when sets A and B have unequal numbers of dwell positions due to introduced
or missed dwell positions by the afterloader.
The uncertainty in the gamma index value is calculated based upon the propagation of
the error of the dwell position determination and the estimated uncertainty in timing,
σΓnij =
√√√√( δnij
Γnij∆x
)2
σ2xiA +
(
τnij
Γnij∆t
)2
σ2tiA (8.1)
where σΓnij is the uncertainty in the gamma index and σxiA and σtiA are the uncertainties
in the dwell position and time calculation. The uncertainty in dwell position is derived
from the position-time histogram described in Chapters 5 and 6. The uncertainty in
dwell time is based on the temporal resolution of the measurement, typically 1 ms.
8.2 Verification of the unmodified plan
A non-specific treatment plan, Plan –1, was created using Nucletron ONCENTRA R©
TPS , delivered using the Nucletron Flexitron R© HDR afterloader and tested with
the MPh. When comparing the treatment plan against the MPh determined dwell
positions and times, it is expected that no errors in afterloader delivery are calculated,
and that the entire measure should pass the position-time gamma analysis.
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Methods
The MPh was imaged using the Philips Brilliance CT - Big Bore scanner at the St
George Cancer Care Centre, Sydney, and the images imported into the Nucletron
ONCENTRA R© TPS. An Axial Helix protocol was used for the CT scan, with a slice
thickness of 1 mm, increment of 0.5 mm. The CT scanner was set to 120 kVp and 250
mAs to obtain a high image signal to noise ratio. Each small MP detector element
could be seen on the 3D image reconstruction, and each detector was selected as a point
for dose calculations in the TPS. The source was then programmed to dwell at various
positions and times inside each of the 20 catheters to create a non-specific treatment
plan, Plan –1, with a maximum dose of 600 cGy to a single detector element. Each
catheter had varying dwell positions and times arranged in the plan in an unsystematic
fashion.
Plan –1 was delivered using the Nucletron Flexitron R© HDR afterloader and measured
by the MPh. Each plan was exported as a DICOM file, preserving the source dwell
and timing information for each catheter and the calculated absorbed dose at each
detector position on the MP. The DICOM file was subsequently read by the custom
software suite to compare the calculated dwell positions and times against the plan
using the position-time gamma analysis.
Results
Figure 8.2 shows the source tracking calculated position and dwelling time in a position
in the catheter verses time for the first catheter, determined by the algorithm described
in detail in previous study. The TPS plan for this catheter is graphed for comparison
and shows good agreement for positions larger than 5 mm from the coordinate origin
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based on the MPh corner detector. While the TPS does not take into account the
motion of the source in transit between dwell points, it is possible to measure this due
to the high speed of the MPh readout system, and is the subject of Chapter 7.
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Figure 8.2: Source tracking measurement and TPS plan for Catheter 1. The position
calculated was relative to the MPh coordinate system.
The calculated and TPS planned dwell position-time pattern for catheter 1 are pre-
sented in Fig 8.3. Uncertainties in the dwell position determination were typically of
the order of 0.2 mm (2 S.D) and are unable to be seen on this graph. Good agreement
between these dwell patterns were seen for the majority of points, except for those
close to 0 mm, due to the edge of FOV effect.
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Figure 8.3: Dwell position frequency histogram and comparison of dwell position tim-
ing pattern for Catheter 1 with the TPS plan.
The average difference between the calculated dwell position and the TPS plan for 86
dwell positions was 0 ± 0.63 mm (2 S.D), taking into account the larger differences due
to the edge FOV effect. When not taking this into account, the average difference was
found to be 0 ± 1.30 mm (2 S.D). Seen in Figure 8.4, the dwell time differences were
found to be less than 0.25 s, and the majority showed that the MPh calculated less
than the expected planned dwell times. It is expected that due to the highly accurate
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internal clock of the electronics used, the error in timing is approximately 1 ns.
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Figure 8.4: Histogram showing the difference in dwell times of the Measured and TPS.
This difference in dwell time is most likely due to a feature of the Nucletron Flexitron R©
HDR afterloader that reduces dwell times to compensate for additional dose delivered
while the source is in transit between successive dwell points. In Figure 8.5, the
differences in dwell times are plotted against the interdwell distances, showing that
the difference in dwell time for the subsequent position is proportional to the distance
the source had to travel. An interdwell distance of 0 mm represents the first dwell
position in the catheter, where it is expected to be no change in dwell time.
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Figure 8.5: Difference between calculated and planned dwell times against interdwell
distance.
According to the Nucletron ONCENTRA R© TPS MasterPlan Physics and Algorithms
manual [97], it is assumed that this afterloader drives the source at a speed of 50 cm/s
and for an interdwell distance of 50 mm the dwell time is reduced by a maximum of 0.1
s. It is noted that this feature may not be seen in some afterloaders. The calculated
dwell time differences are larger than expected, but values of the average source speed
varied from 12.5 - 37.5 cm/s were previously reported by the author [16]. Although a
different afterloader was used in that study, if it is assumed they share similar average
source speeds, then the variation in dwell time difference can be justified.
8.2. Verification of the unmodified plan 135
0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0
0 . 0 0
0 . 2 5
0 . 5 0
0 . 7 5
1 . 0 0
1 . 2 5
1 . 5 0
 
 
C a t h e t e r :  1
 G a m m a
 G a m m a  =  1
Po
siti
on
-Ti
me
 G
am
ma
 In
de
x
D w e l l  P o s i t i o n  ( m m )
Figure 8.6: Gamma analysis for Catheter 1 (Criteria: DTA = 1.3 mm, TTA = 0.3 s).
The software suite, BrachyPix, determines the dwell position and times for all the
catheters and compares them against the treatment plan using the position-time
gamma analysis. By applying the equations described in Table 8.1 to the dwell pattern
of Catheter 1, the gamma index values for each dwell position were calculated and are
shown in Figure 8.6. Taking into account the differences between the calculated dwell
position and times, the DTA and TTA were set to be 1.3 mm and 0.3 s, respectively.
8.3. Verification of the modified plan 136
0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0
0 . 0 0
0 . 2 5
0 . 5 0
0 . 7 5
1 . 0 0
1 . 2 5
1 . 5 0
 
 
Po
siti
on
-Ti
me
 G
am
ma
 In
de
x
D w e l l  P o s i t i o n  ( m m )
A l l  C a t h e t e r s
 G a m m a
 G a m m a  =  1
Figure 8.7: Gamma analysis for all catheters (DTA = 1.3 mm, TTA = 0.3 s).
Applying the gamma index to all 20 catheters, it can be seen from Figure 8.7 that the
majority of the treatment (95%) have gamma values of less than or equal to 1. There
are 5 points with gamma values greater than 1, but they are considered to pass, due
to their uncertainty, derived from Equation 8.1.
8.3 Verification of the modified plan
A copy of Plan – 1 was created and modified by a member of the hospital medical
physics staff, without the supervision of the authors, and an undisclosed number of
changes were made. This modified version of the plan was named Plan – 2. Any
differences in dwell position and time larger than the position-time gamma index
criteria would result in a gamma value of greater than 1, and indicate that a simulated
afterloader error had been detected.
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Methods
The plan was altered by the inclusion of new dwell points, points shifted or removed;
and some dwell times lengthened or shortened, to simulate a scenario where there
is a misadministration by the afterloader. The plan was again delivered using the
Nucletron Flexitron R© HDR afterloader and calculated by the MPh.
Results
Plan –2 was measured using the MPh and based on the results from the position-time
gamma analysis, an estimated 11 changes were believed to have been made to the
treatment plan. One change to Catheter 3, seen in Figure 8.8, was the addition of a
dwell position. This introduced position was seen to be at 17.2 ± 0.1 mm from the
coordinate origin, with a dwell time of 14 s.
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Figure 8.8: Comparison of dwell pattern for Catheter 3 against the TPS plan.
The introduction of the new dwell position causes the gamma analysis of this catheter,
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seen in Figure 8.9, to fail the pass-fail criteria. A gamma value of 12.0 ± 1.9 was
calculated based on the agreement between the introduced calculated position and the
nearest TPS planned dwell point (position = 24.3, time = 11.3).
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Figure 8.9: Gamma analysis for Catheter 3 for the modified plan (Criteria: DTA =
1.3 mm, TTA = 0.3 s).
Assessing the position-time gamma index for the entire modified treatment to the
original plan, Figure 8.10 indicates 11 modified dwell positions. Upon analysing the
modified treatment plan DICOM, these 11 alterations were verified to indeed be the
introduced changes.
8.4. Dose calculation comparisons 139
0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0
0
5
1 0
1 5
2 0
2 5
3 0
3 5
4 0
 
 
A l l  C a t h e t e r s  -  M o d i f i e d  P l a n
 G a m m a
 G a m m a  =  1
Po
siti
on
-Ti
me
 G
am
ma
 In
de
x
D w e l l  P o s i t i o n  ( m m )
Figure 8.10: Gamma analysis for all catheters for the modified plan (Criteria: DTA =
1.3 mm, TTA = 0.3 s).
8.4 Comparisons between "Magic Phantom"
calculated dose, TPS and EBT3 film dose
BrachyPix performs dose calculations based upon the TG-43U1 protocol, and was
tested to ensure that based upon the TPS planned dwell positions, times and dose cal-
culation points, BrachyPix agreed with doses determined by Nucletron ONCENTRA R©
TPS. Once BrachyPix calculations were verified, two dimensional dose maps were gen-
erated based upon the measured Plan – 1 and Plan – 2 deliveries, and compared to
dose maps for these plans and dose calculated using EBT3 film.
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Methods
In planning, each MP detector coordinate was selected for point dose calculations and
stored inside the DICOM file, along with the source dwell positions and times. The
DICOM file of the original plan was read by the MPh software, and the coordinates
and value of each dose calculation point were acquired. A direct comparison between
the values within the DICOM was performed for 121 points using the dose calculation
engine of the software.
Using the software, dose maps were generated along the MPh detector plane for the
original treatment plan, Plan – 1, the measured treatment based upon the calculated
dwell positions and times, and for the modified treatment plan, Plan –2. Plan – 1 was
then measured by replacing the MP detector with EBT3 film. The film was cut to
match the size of the MP and markings were made for alignment. Both the film and
MP were later scanned using the scanner, so that the film dose map positions could
be registered to those calculated by the MPh software. The change in optical density
was converted to dose using the calibration curve reported in Chapter 3.
Each dose map had a size of 10×10 cm2, with pixel dimensions of 0.5×0.5 mm2. The
maps were compared using the 2D gamma analysis, proposed by Low et al. [96], with
varying dose difference and distance-to-agreements criteria.
The total transit dose for the MPh diode positions was also estimated by performing
dose calculations for each calculated source position between dwell positions, assuming
a discrete source movement between consecutive frames.
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Results
Good agreement was found between the MPh software estimated doses for the 121
positions and the TPS, with all values within ± 0.75% (2 S.D), suggesting that the
dose calculation engine based on the predetermined dwell positions and time was
correct. The calculated 2D dose map for the calculated dwell positions and times of
the original plan is shown in Figure 8.11. The film was irradiated using Plan – 1 and
processed to create a map with the same dimensions and resolution as the others.
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Figure 8.11: Dose to the MPh detector plane calculated using TG-43U1, based upon
calculated dwell positions and times, without transit dose contribution.
BrachyPix was additionally capable of estimating the contribution of the total transit
dose for this plan by calculating the dose delivered for the sampled transit positions
only. Seen in Figure 8.12, the total maximum transit dose was calculated to be 18 cGy
for the measured plan, based on a source activity of 18 mGy.m2.h−1. This represents
an average of 4.8 ± 2.3% increase in dose delivered when compared to the total dose
delivered from the dwell positions only on a point-by-point comparison. This result
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is dependent on the source activity and for this particular plan the transit dose con-
tribution could double when delivered directly after a source exchange, assuming the
same transit times.
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Figure 8.12: The calculated total transit dose contribution, delivered to the MPh
detector plane for the unmodified treatment plan.
All dose distributions were compared using the 2D gamma analysis for varying dose
difference and distance to agreement criteria, and the results are shown in Table 8.2.
The global dose difference value was calculated based upon the maximum dose in the
compared maps. It is seen that using a dose difference and distance to agreement of
4% and 3 mm, a pass rate of over 95% could be achieved for both the MPh dose map
without the transit dose and the film for the original plan. Considering the transit
dose contribution improved the pass rate, with a value of above 90% for all criteria
examined, as found in Table 8.2. This suggests that the reduction of the dwell times
is an appropriate method to compensate for the total transit dose when executing this
plan. Using lower criteria values reduced the pass rate for film, most likely due to the
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registration of the film position to the MPh and the associated uncertainty in the film
dose calculation.
Gamma pass rate (%) for DDA and DTA criteria
Evaluated maps 2% / 2 mm 3% / 3 mm 4% / 3 mm
Measured by the MPh - Plan – 1 80.6 94.0 98.3
Measured by the MPh - Plan – 1
with transit dose correction
90.6 98.3 99.9
EBT3 film - Plan – 1 58.7 82.2 95.8
Measured by MPh - Plan – 2 30.1 40.3 49.3
Table 8.2: The comparison of calculated dose maps against the reference TPS planned
dwell positions and times
Calculating the pass rate for the map of Plan – 2 gave a pass rate of 49.3% for the
criteria (DDA = 4%, DTA = 3 mm), which is to be expected due to the simulated
errors in afterloader delivery, confirming the gamma analysis is capable of detecting
the introduced errors. Performing the dose calculations and using the 2D gamma
analysis to compare the dose profiles allowed for additional verification of the treatment
delivery, which could also be used to verify the dose calculations of the treatment
planning system.
8.5 Discussion and conclusion
The MPh and software has demonstrated its ability to verify the created treatment
plans for HDR brachytherapy in terms of dwell position and times. For the original
plan, Plan – 1, the MP system was capable of measuring all dwell points and times
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and the majority were found to be within 0.93 mm and 0.25 s, respectively, from the
plan.
Using a distance-to-agreement and time-to-agreement criteria of 1.3 mm and 0.3 sec-
onds, respectively, for the position-time gamma metric, all modifications made to
the plan were able to be identified. This demonstrates the proof of concept of the
position-time gamma metric for errors larger than the distance-to-agreement and time-
to-agreement criteria, and allows for a quick and easy assessment of the afterloader
performance.
When taking into account the FOV effect it was found that the difference in dwell
positions was 0 ± 0.63 mm (2 S.D), agreeing with the results found in Chapter 6.
When not considering this effect, this increased to 0 ± 1.30 mm, which is the basis for
the distance-to-agreement criterion in the position-time gamma analysis. The use of
the 0.3 second time-to-agreement criterion is based upon the afterloader reducing the
dwell times to compensate for the transit time, but in afterloaders where this is not a
feature, this criterion could be lowered substantially.
With adjustments to the treatment plan so that dwell positions fall between the 10 – 90
mm length of the catheter, differences between the calculated and planned dwell times
should be less than 0.7 mm. Dwell time differences that are significant and can not be
explained due to the source transit time or large differences in dwell position should
prompt user action to further investigate the afterloader performance. Currently, the
MPh tolerances in dwell position and time are much smaller than the majority of
experimental QA methods described in Chapter 2, with the additional benefit of a
completely automatic software analysis.
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The addition of the TG-43U1 protocol calculation to BrachyPix allows for dosimetric
information to be determined based upon the calculated treatment plan. This was
found to be in agreement with the TPS calculated values and with experimental EBT3
film results. As dose is calculated solely on the MP plane by the software, dose to the
target and to organs at risk could be recalculated by the treatment planning system
based upon the calculated dwell positions and times, allowing for the an assessment
of the effect of these treatment delivery errors.
Using this system, potential studies could assess the clinical implications of the deter-
mined transit dose by prospectively testing patient plans and assessing the additional
dose delivered to the target volume and organs at risk. By developing BrachyPix
to accept planned patients treatment images, contoured volumes and catheter recon-
structions, the total and transit dose could be calculated based on the MPh measured
dwell positions and times, and transit motion. Analysing multiple treatments with
different catheter numbers and source activities, it would be possible to determine the
implications of the transit motion on the delivered dose and what amount is accept-
able. If warranted, it would the be possible to assess the transit dose to be delivered
to the patient yet to be treated when used for pre-treatment quality assurance.
Chapter 9
Pretreatment verification of clinical
patient plans
As HDR brachytherapy plans become increasingly complex, it is important to develop
pretreatment delivery verification methods that ensure the optimum treatment of pa-
tients [15]. While it would be ideal to perform an in-vivo verification during treatment,
a pretreatment confirmation of the planned delivery could also ensure that there are
no deviations between the source dwell times and positions, or incorrect lengths of
catheters and step sizes used.
When estimating the total time for a pretreatment verification of a patient plan, it
is necessary to consider the following factors: the time needed to set up the system,
the planned prescription dose to the target, the HDR source activity at the time
of measurement, the numbers of catheters planned, and the total dwell times based
upon the prescription dose. As the execution of a treatment plan by the remote
afterloader can take up to 30 minutes, the medical staff may not choose to deliver the
full prescription dose for a pretreatment verification to the QA device when a reduced
dose may result in similar outcomes within a shorter time.
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This chapter seeks to evaluate the performance of the MPh QA system in evaluating
real patient plans with varying numbers of catheter and prescription doses, for breast,
prostate and vaginal treatments.5 Six unique clinical patient plans were selected, based
on their treatment type, and anonymized for testing in Nucletron ONCENTRA R©
TPS. The dwell times were set to match the patient post-treatment log, ignoring any
variation in source strength between the plans.
All plans were delivered using the Nucletron Flexitron R© HDR afterloader (Nucletron,
an Elekta company, Elekta AB, Stockholm, Sweden) at the St George Cancer Care
Centre, Sydney. Each patient plan was measured twice: first at 100% of the pre-
scription dose and then at 20%. Measurements were analysed using BrachyPix, and
evaluated using the position-time gamma index to determine any changes in measure-
ment quality.
9.1 Full plan delivery
Each of the selected treatment plans were delivered to MPh at the full prescription
dose. The measured delivery was then compared to the plan and analysed using the
introduced position-time gamma index.
Methods
Six patient plans (two prostate, two breast and two vaginal plans) were selected to
cover a range of sites treated using brachytherapy. These types of treatments can have
5 This chapter has been published in Biomedical Physics & Engineering Express:
A. Espinoza, M. Petasecca, D. Cutajar, I. Fuduli, A. Howie, J. Bucci, S. Corde, M. Jackson, M.
Zaider, M. L. F. Lerch, and A. B. Rosenfeld, "Pretreatment verification of high dose rate brachyther-
apy plans using the "magic phantom" system," Biomedical Physics & Engineering Express, vol. 1,
no. 2, 025201, 2015.
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varying numbers of catheters: the vaginal plans used 1 catheter and an irradiation
time of approximately 8 – 9 minutes, breast plans had 10 catheters and a time of 30
seconds per catheter, and the prostate plans used up to 19 catheters with a time of
approximately 20 seconds per catheter. Each plan used a step size of 5 mm. The
six plans were sequentially delivered, measured and analysed using the position-time
gamma index.
Results
Each patient plan was measured using the MPh, and analysed using the source tracking
method, with the dwell position and time calculation previously described in Chapters
5 and 6. The treatment plan DICOM file was imported into BrachyPix to extract the
catheter number, dwell position and timing information and perform the position-time
gamma analysis.
Figure 9.1 a) shows a histogram of the difference in dwell positions between those
determined by the software tool kit and the TPS. The average difference of the 363
dwell positions across the 6 plans, was found to be -0.01 ± 0.72 mm (2 S.D). The
histogram of the difference in dwell times is shown in Figure 9.1 b) and has an average
difference of -0.03 ± 0.11 s (2 S.D).
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Figure 9.1: Histogram showing the difference in dwell positions and times between
the calculated results and TPS for all the calculated dwell positions of the six patient
plans.
Figures 9.2 a-f) show the results of the position-time gamma index for the six pa-
tient plans, with the origin of the dwell position axis equal to the first dwell position
selectable in the TPS. Using a distance-to-agreement and time-to-agreement criteria
based upon the absolute maximum differences of 1.3 mm and 0.3 s, respectively, all
measurements achieved a pass rate of 100%, which showed that no delivery errors had
been detected. Two plans, Breast – 2 and Prostate – 2, had gamma index values close
or over 1, but were considered to pass due to the uncertainty calculated.
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Figure 9.2: The position-time gamma analysis for the measured six patient plans
(Criteria: DTA = 1.3 mm, TTA = 0.3 s).
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The time structure for each measured plan is shown in 9.1 which shows how many
catheters were used by the remote afterloader in treatment delivery for each plan, the
total planned dwell times, the total calculated times, and the total time of irradiation
from when the source is first detected by the MPh, to when it leaves the final catheter.
Treatment
plan
Number of
catheters
Sum of
planned dwell
times (s)
Sum of
calculated
dwell times (s)
Total
treatment time
(s)
Breast – 1 10 323.6 322.8 572.0
Breast – 2 10 158.4 157.5 408.8
Prostate – 1 18 355.4 352.8 810.8
Prostate – 2 19 356.4 353.4 835.9
Vaginal – 1 1 486.7 487.8 489.4
Vaginal – 2 1 518.0 519.2 520.7
Table 9.1: Planned and calculated dwell times and total time for verified plans.
Using the Nucletron Flexitron R© HDR afterloader, there is a 25-30 s delay while the
source is inside the afterloader safe between entering the catheters, as the afterloader
drives the check cable through each catheter to test for obstructions. For safety rea-
sons, this check cable run cannot be switched off on this afterloader in clinical op-
eration. With a higher number of catheters the total treatment time increases, and
currently cannot be avoided. The total treatment transfer time (Ttran) was measured
and can be calculated for n-catheters (n > 1) by using a linear model
Ttran = a× (n− 2) + b (9.1)
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where a = 24.8 ± 0.6 s and b = 35.1 ± 2 s, derived from the measurement analysis.
9.2 Accelerated delivery
The prescription dose for each plan was reduced to decrease the time needed for pre-
treatment QA. The feasibility of this method was assessed by comparing the resulting
position-time gamma analysis and any differences in afterloader delivery performance.
Methods
For each of the six patient plans, the prescription dose was decreased by a factor of
80% to reduce the total irradiation time, resulting in faster delivery execution. This
reduction was selected to test the feasibility of this method, but other reductions could
be used to ensure that a delivery takes no longer than a specified time, e.g., no more
than 5-10 minutes. Each modified plan was measured using the MPh and the results
of the position-time gamma analysis were compared to those of the full prescription
dose.
Results
The prescription dose for each of the six patient plans was reduced by 80% using the
TPS and measured using the MPh. A comparison of the results of the dwell position
and timing analysis to the plans is seen in Figures 9.3 a) and b). The average difference
between the calculated and planned dwell positions and times were found to be -0.01
± 0.73 mm (2 S.D) and -0.05 ± 0.10 mm (2 S.D) respectively, and are in agreement
with the results found in the previous section.
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Figure 9.3: Histogram showing the difference in dwell positions and times between the
calculated results and TPS for all the calculated dwell positions using the accelerated
method.
The differences in position may be due to the accuracy of the MPh system in deter-
mining the source position but could also be due to possible shifts in the dwell position
from slight variations in the individual transfer tube length, and the reported effect
of the flexing of these transfer tubes [37,38]. While the effects of the curvature of the
transfer tube were not evaluated in this study, the measurements were set to replicate
a clinical delivery, with the phantom placed on the treatment couch at an appropriate
height and distance from the afterloader. The differences in dwell times is attributed
to the Nucletron Flexitron R© HDR afterloader compensating for the source transit time
as described in Chapter 8.
The position-time gamma analysis of the accelerated version with the reduced prescrip-
tion doses are seen in Figures 9.4 a-f). It can be seen that, although the prescription
dose was reduced by 80%, the accelerated plan was able to be measured and give a
comparable gamma analysis result. All treatment measurements had a pass rate of
100% using the same distance-to-agreement and time-to-agreement criteria.
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Figure 9.4: The position-time gamma analysis for the measured accelerated six patient
plans (Criteria: DTA = 1.3 mm, TTA = 0.3 s).
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The total treatment time reduction was found to be much less than 80% for multiple
catheters, as seen in Table 9.2. Although the sum of the dwell times had decreased,
the time taken for the cable check runs were the same as the full prescription dose
plans. Also shown in this table, as the prescription dose was reduced, many dwell
positions were neglected by the remote afterloader.
This is due to two reasons: those dwell times originally less than 0.5 seconds were
rounded down to 0 by the TPS (this occurred 30 times across the 6 patient plans) and
the reduced dwell times were further shortened by the afterloader compensating for
time taken to step the source between dwell positions. If the time for stepping motion
was larger than the reduced dwell time, the position was omitted (this occurred 15
times across the 6 patient plans). At the cost of increased total measurement time,
those dwell times affected by the transit motion could be rectified by adjusting the
reduction in prescription dose to ensure these dwell positions are executed.
Treatment
plan
Sum of
planned
dwell times
(s)
Sum of
calculated
dwell times
(s)
Number of
dwell
positions
omitted
Total
treatment
time (s)
Total time
reduction
(%)
Breast – 1 60.8 59.1 3/51 308.2 46.1
Breast – 2 31.2 29.9 1/37 281.2 31.2
Prostate – 1 69.8 67.0 16/116 551.8 31.9
Prostate – 2 68.8 66.5 25/140 575.1 31.1
Vaginal – 1 99.2 99.3 0/9 100.7 79.4
Vaginal – 2 103.6 103.51 0/10 105.2 79.8
Table 9.2: Planned and calculated dwell times and total time for accelerated plans.
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The prostate – 2 plan had 25 dwell positions omitted, 7 of which were due to the
afterloader compensating for the time taken to move the source between the dwell
positions, and the remaining omissions due to the dwell time being rounded down to
0. From the presented data, it is possible to see that for the vaginal single catheter
case, the time reduction in comparison with the original check is approximately 80%.
A similar time reduction could be achieved for breast and prostate treatment if the
cable run checks were avoided in service mode.
9.3 Discussion and conclusion
It has been shown that using the MPh HDR pretreatment QA device, it is possible to
verify patient plans, with all calculated dwell positions and times were found to lie in
0.7 mm and 0.3 s, respectively. While treatment verification can be time consuming
due to the execution of the plan by the afterloader, the presented method of reducing
the time by a large reduction in the plan prescription dose may be an adequate solution.
By using a reduced prescription dose, it was seen that there were no large discrepancies
introduced to the dwell position when assessed by the position-time gamma analysis.
The concept of accelerated verification has the advantage that it can increase the
throughput of testing multiple treatment plans, especially when using low activity
sources that typically result in longer irradiation times. It can have substantially
shorter measurement times with very similar outcomes to the full prescription dose
plan, in terms of the differences between dwell positions and times, and the position-
time gamma analysis.
If it were possible to remove the cable check run for each catheter in a special diag-
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nostic QA mode of the afterloader, the practicality of this method would be greatly
enhanced. This mode should perform a single complete cable check run, prior to
multiple measurements, to ensure that the transfer tubes are connected correctly and
that no defective catheters were used, minimizing the risk of potentially damaging the
source and its cable.
The obvious drawback is that the actual patient plan is not verified. This may result
in an incorrect evaluation of the quality of treatment delivery to be expected to the
patient at the time of treatment. As shown in these results, a significant number of
dwell positions in the plan which had short dwell times were rounded to 0 by the TPS
when the reduced time was less than 0.1 of a second. The significance of these omitted
dwell positions must be evaluated in the context of the rest of the treatment plan.
This method gives the operator the option of accelerating the treatment check, allow-
ing for the verification of source dwell positions and the scaled dwell times against the
treatment plan. As the MPh has each catheter numbered, it may distinguish when
catheters have been incorrectly connected by the transfer tubes and identify the cause
of a gamma criteria failure. Scaled dwell times below 0.1 s were omitted by the treat-
ment planning system as a result of using the fixed 80% prescription dose reduction
for this feasibility test. In practice, the user would set this reduction to ensure a more
preferable execution of the plan.
Chapter 10
The feasibility of the "Magic Plate"
for in-vivo source tracking
The previous chapters have assessed the role of the "Magic Plate" for HDR brachyther-
apy pretreatment quality assurance. The aim of this final experimental chapter is to
project the source tracking technique into the application of in-vivo verification and
to explore possible limitations of this method. The preliminary testing of this con-
cept will apply the source tracking method to large distances within Solid Water R©,
simulating the tracking of the source inside the human body.
All plans were delivered using the Nucletron Flexitron R© HDR afterloader (Nucletron,
an Elekta company, Elekta AB, Stockholm, Sweden) at the St George Cancer Care
Centre, Sydney.
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10.1 Tracking the HDR source in body
Due to the positioning of the patient during treatment, there are few places where the
placement of the MP detector could be feasible. A practical option, as seen in Figure
10.1, could be to place the MP directly beneath the patient being treated, possibly
inside the treatment couch or a patient transfer system like the Zephyr HDR Patient
Positioning and Transfer System [98]. A specialised gurney with the MP could be
used during both the CT imaging of the patient and in treatment, to obtain accurate
information about the patient anatomy and the catheter positions relative to the MP
detector.
Rectum
Catheters
Bladder
Pubis
Prostate
Couch
“Magic Plate”
Sacrum
Figure 10.1: A possible placement of the MP relative to the human body.
The prostate, as described in Chapter 2, is located deep inside the pelvis, between
the bladder and the penis. Placing the MP detector underneath the patient during
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treatment would mean that the distance from the HDR source to the MP detector
could be between 90 - 150 mm. For the verification to be accurate, the source tracking
method must work at these large distances within the body.
The source tracking algorithm was designed to calculate the 192Ir source position within
Solid Water R©. While tissue can be approximated by water, for prostate cancer in
particular, there are different mediums between the source and the MP that would
have to be taken into account during the source tracking procedure. Mediums such as
air gaps, bones and introduced materials, could change the radiation field measured
outside the body.
Air gaps, that may be inside an empty rectum, are less attenuating than tissue and
result in a larger flux of photons and thus a larger current generated at the MP.
This would cause the tracking algorithm to determine the source to be closer than
its actual position. Bones, such as the sacrum at the end of the spine, would have a
higher effective atomic number than water, and would result in a decrease in current
generated due to higher radiation attenuation. This would cause the MP algorithm to
calculate the source position further away.
During the surgical insertion of the catheters, a transrectal ultrasound (TRUS) probe is
typically used to guide the placement of the HDR catheters into the prostate. In some
clinics, the image obtained from the TRUS probe is used to perform the treatment
planning, as opposed to the use of the CT image. The physical placement of the
TRUS probe may lead to a distortion of the shape of the rectum and prostate, and so
to ensure that the dose calculations and planning are valid, the TRUS probe is kept
inside the patient during treatment. The probe, made of plastic and ceramic with a
large brass backing, would also act as a attenuator of the radiation and as a source of
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scatter, between the 192Ir source and the MP detector.
10.2 Source tracking feasibility
The feasibility study performed in Chapter 4 showed that the 192Ir source was able to
generate current in the MP detector at distances up to 150 mm. In this chapter, the
HDR tracking algorithm is applied to measurements of the source position at SDD of
120 mm, inside a SW phantom, with varying measurement configurations to simulate
tracking in the human body.
Materials
Measurements were performed using two additional materials, a TRUS probe without
it’s plastic casing, and a PVC bone substitute.
The TRUS probe
The TRUS probe used in this experiment was the Endocavity Biplane Transducer
Type 8848 produced by BK Medical, used for transrectal scanning for brachyther-
apy treatments, Figure 10.2. It features two arrays for transverse and sagittal ultra-
sound transducers that can be used for the separate or simultaneous imaging of both
planes. It is used to determine the prostate volume, and for monitoring the insertion
of catheters during the procedure.
10.2. Source tracking feasibility 162
Figure 10.2: BK Medical Endocavity Biplane Transducer Type 8848 probe.
Underneath the TRUS probe casing there are the two arrays for the ultrasound imag-
ing, and a 110×15×3 mm3 bar of solid brass. The brass is used as an absorber to
improve the ultrasound image quality by blocking the reflections in the incorrect im-
age plane. Brass is an alloy of copper and zinc, and thus has an effective atomic
number between 29 – 30, depending on the exact composition. It is therefore assumed
that the brass inside the probe would be a large attenuator of the radiation field, and
a wide scattering source inside of the phantom.
The PVC bone substitute
Polyvinyl chloride (PVC) was selected as a surrogate material to investigate the effect
of the sacrum on the radiation field measured by the MP detector on the surface of
the body. While PVC is not a standard bone substitute in medical physics, its low
cost, availability and equivalent electron stopping power and attenuation coefficient
over the 192Ir energy spectrum, it was selected for use in this study.
The sacrum is made of cancellous bone, which is assumed to be similar to the cortical
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bone composition estimated by the International Commission on Radiological Protec-
tion (ICRP) [99]. The compositions of cortical bone, estimated by the ICRP, and PVC
are presented in Tables 10.1 and 10.2.
Element Atomic number Fractional weight
Hydrogen 1 0.047234
Carbon 6 0.144330
Nitrogen 7 0.041990
Oxygen 8 0.446096
Magnesium 12 0.002200
Phosphorus 15 0.104970
Sulfur 16 0.003150
Calcium 20 0.209930
Zinc 30 0.000100
Table 10.1: The elemental composition of the ICRP cortical bone [99].
Element Atomic number Fractional weight
Hydrogen 1 0.048380
Carbon 6 0.384360
Chlorine 17 0.567260
Table 10.2: The elemental composition of PVC. Data obtain from NIST database [100].
The different elements in PVC and cortical bone have varying photon interaction cross-
sections. The NIST database of x-ray mass-energy absorption coefficients features data
on both PVC and the ICRP cortical bone, and these were compared over the energy
range of 1 - 1000 keV [77]. Figures 10.3 a) and b) show that, over this energy range,
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PVC exhibits a similar behaviour to bone at energies larger than 100 keV.
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Figure 10.3: Comparison between PVC and ICRP cortical bone mass-energy absorp-
tion coefficients.
A software tool kit was developed by Taylor et al. [101], named auto Zeff , to perform
a robust, energy dependent calculation of the effective atomic number, Zeff , of any
material. The calculation is performed by considering the photon interaction cross
sections for elements Z = 1 – 100 over then energy range of 10 keV to 10 GeV, and
determining the atomic cross section of composite materials. The software is capable
of determining the average Zeff over an energy range of 10 keV to 1 GeV, and can also
give a spectrum weighted Zeff . Using the compositional elements of cortical bone and
PVC, the 192Ir spectrum weighted Zeff for each material was calculated to be 5.34
and 5.41, respectively.
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50 mm
10 mm
21 mm
55.9 mm
Figure 10.4: The dimensions of the PVC bone substitute.
The design of the PVC substitute is shown in Figure 10.4. The approximate shape
and dimensions of the sacrum were obtained by comparing 5 CT scans of male pa-
tients treated for prostate cancer by HDR brachytherapy. It is noted that this a very
simplified design, as it does not take into account the curvature of the sacrum, but is
likely to be suitable for this feasibility study.
The density of cortical bone is estimated to be 1.85 g/cm3, which differs to PVC,
which is 1.30 g/cm3. To compensate for the different densities, the thickness of the
PVC substitute was increased to 21 mm, from the 15 mm thickness estimated from
the CT images. A CT scan of the PVC substitute found that the material had an
electron density of 1.447 relative to water, which was similar to the values of 1.473
and 1.707 for bone substitute CB2 50% CaCO3 and cortical bone substitute, part of
the Gammex 467 Tissue Characterization Phantom (Gammex Inc., Middleton, WI,
U.S.A), used in the QA of the CT scanner.
Methods
The MP was used to perform measurements in the four configurations shown in Figure
10.5. The HDR source was programmed to drive towards the catheter tip at a 5 mm
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step size, with a dwell time of 2 seconds at each dwell position. An attempt was made
to ensure that all pieces of SW were aligned on top of each other, as deviations along
the catheter x- and y-coordinates would hinder the comparison between cases.
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(a) Total Solid Water R© volume.
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(b) Solid Water R© with an air gap 60 mm above
the MP.
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(c) Solid Water R© with the TRUS probe 60 mm
above the MP.
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(d) Solid Water R© with the PVC triangle 35 mm
above the MP.
Figure 10.5: The four measurement configurations.
The air gap, Figure 10.5 b), was created by placing two 30×15×20 mm3 pieces of SW
onto the stack, and separating them perpendicular to the catheter by 20 mm. These
pieces of SW allowed for the placement of both the TRUS probe in Figure 10.5 c) and
the PVC triangle in Figure 10.5 d).
To minimise the statistical fluctuations in the current due to the low event rate, the
integration time of the AFE DAQ system was set to 9920 µs. As a consequence, the
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measurement frequency was set at 100 Hz, reducing the temporal resolution to 10 ms.
Results
The current generated in the central MP detector over the entire source movement is
shown in Figure 10.6. It is seen that both the PVC bone substitute and TRUS probe
attenuated the radiation field, while the air gap increased the measured current, when
compared to the SW scenario. The air gap configuration measured an average current
increase of 15.5 ± 2.2%, while the PVC and TRUS probe decreased the measured
current by 3.7 ± 1.8% and 8.7 ± 1.7%, respectively. It is expected that this variation
in response will diminish the accuracy of the source localisation procedure.
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Figure 10.6: The current measured by the central MP detector for the four configura-
tions.
The results of the source tracking along the y-coordinate are shown in Figures 10.7 a),
b), c) and d). All four results seem to follow the expected position of the HDR source
when the source is inside the centre of the MP FOV, while the SW case and the air
gap begin to differ at the edges. The effect of the attenuating PVC bone and TRUS
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probe seems to have little bearing on the y-coordinate tracking, and appears to be an
improvement on the SW and air gap case.
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Figure 10.7: Results of the source tracking along the y-coordinate a) in SW, b) in SW
with air gap, c) in SW with PVC, and d) in SW with TRUS probe.
The catheter x- and z-coordinates were fixed during the measurement to x = 50 mm
and z = 100 mm, and it was assumed the source coordinates would be constant over
the measurement. However, Figures 10.8 a) and b) show that the source localisation
is being calculated incorrectly due to the placement of the inhomogeneous materials
and their effect on the measured radiation field.
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(a) The x-coordinate.
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(b) The z-coordinate.
Figure 10.8: Results of the source tracking along the a) x-coordinate, and b) z-
coordinate.
The most likely cause of the differences in the source tracking results is the effect of
the varied detector responses due to the materials. By integrating the response in all
of the MP detectors over each measurement, a comparison could be made for the PVC,
air gap and TRUS probe against the SW configuration. The integral responses of the
three configurations with inhomogeneities were divided, detector by detector, by that
of the SW measurement, and graphed in Figure 10.9. The uncertainty of the integrals
were calculated based off the standard deviation of 3 measurements per configuration
and were found to be less than 1%.
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(a) The air gap/SW.
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(b) The PVC bone substitute/SW.
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(c) The TRUS probe/SW.
Figure 10.9: The comparison of the integral MP response a) the air gap to SW, b) the
PVC bone substitute to SW and c) the TRUS probe to SW.
Figure 10.9 a) compares the air gap to the SW integral and shows a large increase in
signal down the middle of the MP detector, where the air gap had been placed, at
approximately x = 50 mm. Detectors outside the direct path of the radiation from
the source to the air gap also had an increase in signal of over 5 – 6%. The PVC bone
substitute decreased the integral response by up to 5%, forming a projected image at
the approximate placement of the material in Figure 10.9 b). The TRUS probe, in
Figure 10.9 c), was seen to attenuate the radiation field up to 10%, with the effect
most apparent at detectors directly underneath it.
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10.3 Discussion and conclusion
The results of the in-vivo feasibility study show that it was possible to estimate the
source position at large distances when the source was close to the centre of the MP
FOV. The accuracy of the results of the estimation procedure was, however, limited by
the following factors: the physical size of the MP detector array, the reduced signal-
to-noise ratio at large distances, and the introduction of inhomogeneous materials
between the HDR source and the detector itself.
To improve the source position calculation, the responses from the majority of the
MP detectors were used to compensate for the relatively uniform dose profile when
the HDR source was at large distances. Figure 10.10 shows that dose profile becomes
flatter and wider for increasing source-to-detector distances, when normalised to the
maximum dose calculated by the TG-43U1 protocol. By including the response of a
larger number of detectors, an improvement to the calculation can be made as a better
shape of the dose profile can be obtained.
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Figure 10.10: The normalised dose profile at different SDDs calculated using the TG-
43U1 protocol.
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When the HDR source is close to the edge of the MP FOV, the algorithm procedure
cannot accurately determine the source position. While using the response of multiple
detectors did improve it, a review of the procedure found that the sum of the squares
of the relative error, Equation 5.4, could not be effectively minimised. A possible im-
provement in later generations of the MP could be to increase the number of detectors
and the size of the FOV, to ensure better coverage of the lengths of the HDR catheters.
As noted earlier in the methods section of this chapter, the integration time for each
measurement was set to 9920 µs, the maximum allowed by the electronics system,
with a dead time of 80 µs. This was done to minimise the statistical fluctuations in
the current generated in each detector by the low event rate of radiation. The low
event rate is due to the amount of radiation fluence in the small cross-sectional area of
the MP detector (0.6×0.6 mm2) and the large SDD. The fluctuations in each detector
response reduces the accuracy of the source localisation procedure, as large spikes can
cause the algorithm to shift the estimated position closer to that particular detector.
It is suggested that to minimise the fluctuations, and thus improve the signal-to-noise
ratio, the detector size could be increased and also biased to increase the sensitive
volume.
The non-tissue equivalent materials was found to change the MP response and hence,
the source position calculation. One of the most important components of the source
tracking method is the conversion of the measured detector response to the estimated
source-to-detector distance. This is performed using a model that was determined
from the results of the percentage depth dose measured inside of a full SW stack,
presented in Chapter 4. It is clear that this model used in the localisation procedure is
currently not capable of handling inhomogeneous materials placed between the source
and detector.
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The placement of the MP detector under the surface of the body may need to be
reconsidered for patients where CT images indicate potential issues. With further
research, the effect of the materials may be compensated for by using patient anatomy
information from CT images to adjust the detector response. With the arrival of
model-based dose-calculation algorithms in the near future, it may be possible to take
into account the heterogeneous materials, and use the TPS to predict the dose rate at
the MP detector for comparison.
If this method could not accurately take into account the effect of the TRUS probe, a
possible solution could be to place the detector on the anterior surface of the patient,
as opposed to the previously suggested posterior position. It is expected that the tissue
and pelvic bone structure could be accounted for and the presence of the TRUS probe
would not be an issue. The curvature of individual patients could be compensated by
a moulded bolus, minimising air gaps between the patient and MP detector.
Chapter 11
Conclusion
The aim of this thesis was to develop a quality assurance system for the verification
of HDR brachytherapy delivery. This was realised by adopting an 11×11 array of
silicon detectors and pairing it with a fast electronic readout system. Using a source
localisation algorithm, dwell positions and times were measured in phantom, and then
tested for possible in-treatment monitoring.
11.1 Final summary
Chapter 2 provided a general introduction to prostate cancer and the use of high dose
rate brachytherapy as a treatment option. Following that, a detailed review of the
literature was presented in regards to experimental methods for performing quality
assurance of the source positional and timing accuracy during treatment delivery. It
concluded that while there has been much research in this area, the current state of
quality assurance does not provide a comprehensive method for verifying the after-
loader delivery, either for pretreatment verification or during patient treatment.
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A description of the proposed HDR quality assurance system was given in Chapter
3. The prototype detector, the "Magic Plate", consisted of 121 silicon epitaxial diodes
in a 2D array, coupled to the AFE DAQ system. A software tool kit, BrachyPix,
was designed to interact with the AFE DAQ system to perform measurements and
data handling, and was also capable of real time HDR source tracking. The software
featured automatic post-processing analysis, allowing for the reconstruction of the
measured dwell positions and times, extracted from the source localisation results.
The feasibility of the MP for HDR quality assurance was studied in Chapter 4. The
MP and AFE DAQ system exhibited a low baseline signal of 1.62± 1.65 pA on average.
This was performed by measuring the integrated current inside the HDR treatment
room, while the HDR source was inside the afterloader, with the room lights off. The
source of this current was most likely generated by radio-frequency interference from
the main power lines and also by the design of the AFE DAQ electronics boards. It
was determined that a minimum of 50 mm of SW material above and below the MPh
is necessary for backscatter material. The system was able to measure the charge
generated within the MP detectors by the 192Ir source over a range of 7 – 151 mm
source-to-detector distance, and was found to agree with the data simulated by Taylor
and Roger [28]. The MP detectors displayed an angular dependence of ± 15% between
the top and bottom face of the diode, but has a less than ± 5% difference for 0 ± 60◦
and 180 ± 60◦.
Chapter 5 details the theory of the source localisation algorithm used in this work. The
source-to-detector distances were calculated based on the response of each detector and
were then compared to the geometric distance between the detector and an estimate
of the source position. An iterative procedure was used to minimise the difference
between the source-to-detector distances and the estimated geometric distances, until
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a good agreement was found. A method for determining the dwell positions and times
was presented that considered the direction of the movement of the source inside each
catheter in the MPh.
The source localisation and dwell position and time calculation procedures were vali-
dated in Chapter 6. By registering EBT3 film to the MP detector and irradiating the
film and detector, measured source dwell positions were compared and found to have a
difference of less than 0.8 mm. It was found that using the source tracking algorithm,
the HDR source transit motion could be determined and that there was a reduction in
measured dwell times due to the afterloader compensating for the source movement.
The MP system showed that it can be used to resolve dwell positions spaced apart by
1 mm or larger, and could be used to determine the dwell time with a 1 ms resolution,
when a 1 kHz measurement frequency was used. It was also observed that, due to the
size of the MP and spacing of the detectors, there was a shift in the estimated source
position when close to the edge of the MP FOV.
Using the developed source tracking algorithm and an increased acquisition frequency,
the instantaneous transit motion of the HDR source was characterised in Chapter
7. The transit speed was found to be non-constant, contrary to the assumptions
made by the afterloader manufacturer and by some previous studies. As the TG-43U1
protocol dose calculations have been implemented into BrachyPix, the transit dose
was determined for the MP plane, and showed that it could be feasible to determine
the additional dose to be received by the target and critical organs.
The MP, inside of the MPh, was used to verify the delivery of two HDR treatment
plans in terms of dwell position and times in Chapter 8. A new metric was introduced,
named the position-time gamma index, and was used to compare the measured dwell
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positions and times to those expected from the treatment plan, allowing for a quick
and easy assessment of the afterloader performance. For the first plan, the MP system
was capable of measuring all dwell points and times and all were found to be within
0.93 mm and 0.25 s. The second plan was a modified version of the first, with simu-
lated afterloader errors introduced to test the performance of the position-time gamma
index. The gamma analysis found that all simulated dwell position and time errors
with differences greater than 1.3 mm and 0.3 s, respectively, could be determined. By
using The TG-43U1 protocol dose calculations based upon the measured dwell posi-
tions and times and comparing them to irradiated EBT3 film using the dose-distance
gamma metric, good agreement was found between the planned and measured dose
maps, when including the estimated transit dose.
Chapter 9 assessed the ability and the time taken to measure six patient plans using the
MP inside of the MPh. The system was able to determine the measured dwell positions
and times from the six patient plans to within 1.3 mm and 0.3 s, respectively. Using the
position-time gamma analysis, the delivery of all measured patient plans were found to
pass this metric with pass rates of 100%. The approach of decreasing prescription dose
gave equal pass rates to the full dose plan when evaluated using the criteria. It was
identified that the total time for treatment verification of the Nucletron Flexitron R©
HDR afterloader is dependent on the number of catheters used, and that a substantial
decrease in the total time for verification could be made by reducing the prescription
dose for plans containing a low number of catheters. The application of this method
may have the ability to streamline pretreatment verification of the afterloader delivery
within the clinical setting.
The final experimental chapter, Chapter 10, detailed the feasibility of in-vivo tracking
of the HDR source while inside of the human body. The study focused on determining
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the source position inside a water equivalent volume at large distances, and by placing
materials between the HDR catheter and the MP detector. The study concluded that
it could be possible to track the source inside of the body, but care was needed when
deciding on detector placement, as the effects of inhomogeneous materials could be
substantial.
11.2 Future Work
The concept of using a multiple diode array detector was tested for high dose rate
brachytherapy quality assurance. This study showed that the prototype detector has
the potential to be a comprehensive quality assurance solution, with further develop-
ment and optimisations. There are a number of potential improvements that could be
made to the system to increase its accuracy and usability.
The first recommended improvement is to the design of the MP diode element. The
angular dependence of the epitaxial diode, while it was characterised, needed to be
compensated for by the source tracking algorithm. Minimising the angular depen-
dence, at least in the top face of the detector, could improve the reliability of the
source tracking method. Another improvement that could be made to the diode el-
ement, is to increase the sensitive area of the detector. With increased area, and by
applying a small reverse bias, the sensitive volume of each detector could be increased,
improving the sensitivity during in-vivo measurements. A larger detector element area
would reduce the ability to perform pinpoint measurements when used in sharp dose
gradients, however, for the in-vivo case this should not be an issue due to the flat dose
profiles.
11.2. Future Work 179
The second recommendation is to increase the total number of diode elements and the
field of view of the detector system. Current technology at the Centre for Medical
Radiation Physics is utilising up to 512 detector elements in a single system, with
development into systems with larger numbers. By increasing the number of detectors
up to 512, the area of the MP could be quadrupled and still achieve a decrease in the
detector spacing. An illustration of a possible future design is shown in Figure 11.1.
Figure 11.1: An illustration of a possible design of the HDR specific MP-512.
The larger field of view could improve the source tracking ability for the entire length of
the HDR treatment catheter, and also improve the source tracking itself with increased
detector redundancy. With a larger field of view, it would not be necessary to place
HDR catheters beneath the MP detector. Instead, all could be placed inside of a newer
designed MPh, above the MP-512 detector, again reducing the effect of the angular
dependence.
The final recommendation is the further development of the BrachyPix software. The
11.2. Future Work 180
software, constructed for this study, was made to be flexible in its use and easily
changeable, such as to perform TG-43U1 dose calculations or to optimise the source
tracking procedure. Later versions of this software should be more targeted to be
used by clinical medical physicists, by being easier to use and provide only clinically
relevant results. It could feature the full integration of patient treatment plans and
CT images, with 3D rendering in real time of the source position inside of the patients’
tumour. Giving the clinical team the ability to see the position of the source inside of
the tumour could be invaluable for in-vivo verification, and could potentially prevent
incorrect treatments.
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